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Nutrient needs are a population-wide distribution, and can vary dramatically from 
person to person. Factors known to influence individual nutrient needs include 
common genetic polymorphisms as well as pregnancy and lactation, physiological 
states that are generally associated with an increased nutrient requirement. This 
doctoral dissertation examines the effects of common genetic variants in choline, 
folate, and vitamin D metabolic pathways on metabolism at recommended nutrient 
intakes. Interactions between genetic and reproductive factors that influence 
metabolism were also examined. While the genetic variants examined herein have 
been studied in conditions of nutrient deprivation or among non-pregnant women, 
these studies extend prior work to conditions of nutrient adequacy that are relevant 
to the population at large and to include pregnancy and lactating individuals, who 
have an increased risk for nutrient inadequacy, and much to gain from adequacy. We 
identified that common genetic variants impairing folate enzymes increase the 
metabolic use of choline for phosphatidylcholine production. In addition, variants in 
choline metabolizing enzymes altered choline dynamics and partitioning. Lastly, 
vitamin D binding protein rs7041 genotype altered vitamin D metabolism in 
pregnant women. Comprehensively, these findings provide evidence for differences 
in metabolism and nutrient needs at recommended intakes, and suggest personalized 
recommendations may be necessary to achieve optimal health and nutrition.  
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CHAPTER 1 
Genetic Impairments in Folate Enzymes Increase Dependence on Dietary Choline for 
Phosphatidylcholine Production At the Expense of Betaine Synthesis* 
Abstract 
Although single nucleotide polymorphisms (SNPs) in folate-mediated pathways predict 
susceptibility to choline deficiency during severe choline deprivation, it is unknown if effects 
persist at recommended intakes. Thus, we employed stable isotope LCMS/MS methodology 
to examine the impact of candidate SNPs on choline metabolism in a long-term randomized 
controlled feeding trial among pregnant, lactating, and non-pregnant women consuming 480 
or 930 mg choline/d (22% as choline-d9) and meeting folate intake recommendations. 
Variants impairing folate metabolism, MTHFR rs1801133 (c.677T); MTR rs1805087 
(wildtype c.66A); MTRR rs1801394 (c.2756G); and MTHFD1 rs2236225 (c.1958A), 
influenced choline dynamics, frequently through interactions with reproductive state and 
choline intake, with fewer genotypic alterations observed among pregnant women. Women 
with these variants partitioned more dietary choline towards phosphatidylcholine (PC) 
biosynthesis via the CDP-choline pathway at the expense of betaine synthesis even when use 
of betaine as a methyl donor was increased. Choline intakes of 930 mg/d restored partitioning 
of dietary choline between betaine and CDP-PC among non-pregnant (MTHFR rs1801133 
                                                
*Ganz	AB,	Shields	K,	Fomin	VG,	Lopez	Y#,	Mohan	S,	Lovesky	J,	Chuang	JC,	Ganti	A,	Carrier	B,	
Yan	J,	Taeswuan	S,	Cohen	VV,	Swersky	CC,	Stover	JA,	Vitiello	GA,	Malysheva	OV,	Mudrak	E,	
and	 Caudill	MA.	 Genetic	 Impairments	 in	 Folate	 Enzymes	 Increase	 Dependence	 on	 Dietary	
Choline	for	Phosphatidylcholine	Production	at	the	Expense	of	Betaine	Synthesis	FASEB	J	2016,	
30(7).	
#Deceased 
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and MTR rs1805087 wildtype) and lactating (MTHFD1 rs2236225) women with “risk” 
genotypes. Overall our findings indicate that loss-of-function variants in folate-metabolizing 
enzymes strain cellular PC production, possibly via impaired folate-dependent PEMT-PC 
synthesis, and suggest that women with these “risk” genotypes may benefit from choline 
intakes exceeding current recommendations. 
Introduction 
Single nucleotide polymorphisms (SNPs) can alter metabolism and utilization of the 
micronutrients folate and choline.1,2 Inadequacy of these nutrients are risk factors for cancer3 
and birth defects,4,5,6 which are pathologies that result from complex interactions between 
genetic and environmental risk factors. Methylenetetrahydrofolate reductase (MTHFR) 
rs1801133, methionine synthase (MTR) rs1805087, methionine synthase reductase (MTRR) 
rs1801394, and Methylenetetrahydrofolate dehydrogenase-
methenyltetrahydrofolatecyclohydrolase-formyltetrahydrofolate synthetase (MTHFD1) 
rs2236225, are common SNPs in enzymes involved in folate-mediated one-carbon 
metabolism that predict increased risk of birth defects as well as risk of choline deficiency and 
onset of fatty liver disease in humans deprived of choline.6,7  
 The relationship between folate enzyme SNPs and choline requirement may arise from 
the overlapping roles of folate and choline in methionine and phosphatidylcholine (PC) 
biosynthesis. While folate is primarily responsible for the remethylation of homocysteine to 
methionine, which generates the methyl donor S-adenosylmethionine (SAM), the choline 
oxidation product betaine also contributes to methionine biosynthesis, particularly in the 
liver8. An increased contribution by choline-derived betaine to methionine biosynthesis may 
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spare folate cofactors for nucleotide biosynthesis. Furthermore, while choline is used for 
phosphatidylcholine (PC) synthesis via the cytidine diphosphate (CDP)-choline pathway, PC 
produced by the phosphatidylethanolamine-N-methyltransferase (PEMT) uses SAM as a 
methyl donor and is therefore dependent upon both folate- and choline-derived methyl 
groups.9,10 Genetic risk factors that increase the nutritional requirement for choline may 
contribute to the pathogenesis of diseases related to one-carbon metabolism.vi,11 
Physiological factors such as reproductive state can similarly influence choline 
requirements. The demand for choline is uniquely high during pregnancy and lactation due to 
rapid membrane biogenesis, methylation of placental and fetal DNA, and brain development. 
Experimental data in humans have shown altered choline partitioning that indicates an 
increased requirement for choline during pregnancy and lactation.12,13,14 For example, 
compared to non-pregnant women, pregnant women use more choline to synthesize PC 
through both the CDP-choline and PEMT pathways and use more of choline-derived betaine 
as a methyl donor.12 Furthermore, maternal choline intakes exceeding current dietary 
recommendations appear to have favorable effects on several physiologic outcomes during 
pregnancy, including placental functioning15 and the fetal response to stress.16 
At present, it is unknown whether the increased need for choline during pregnancy and 
lactation can be compounded by genetic risk. Furthermore, although genetic variation 
modifies disease risk and choline requirements during severe choline deprivation, and the 
MTHFR rs1801133 variant is known to alter the metabolic flux of choline under conditions of 
folate inadequacy,17 it is unknown whether these variants are functionally relevant under 
conditions of nutrient sufficiency. Thus, we sought to evaluate the influence of “risk 
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genotypes” in folate enzymes on choline metabolism among women of differing reproductive 
states and meeting dietary choline and folate intake recommendations (Figure 1). 
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Figure 1. Overview of the metabolic fate of isotopically labeled choline-d9 consumed by 
study participants. SNPs, in squared enzymes, were examined: MTHFD1 [dbSNP: 
rs2236225; c.1958 G > A; p.Arg653Gln; RefSeq NT_026437.13], MTHFR (dbSNP: 
rs1801133; c.677 C > T; p.Ala223Val; RefSeq NT_021937.17), MTR (dbSNP: rs1805087; 
c.2756 A > G; p.Asp919Gly; RefSeq NG_008959.1), MTRR (dbSNP: rs1801394; c.66 A > 
G; p.Ile22Met; RefSeq NG_008856.1). Note that a deuterated methyl group from DMG-
d6 could be added to tetrahydrofolate (THF) by MTHFD1 to produce 5,10-methenyl-THF-
d2 (loss of a deuterium occurs during addition), which might be converted to 5-methyl THF-
d2 and used to methylate homocysteine to produce methionine-d2. Alternatively, the 5,10-
methenyl-THF-d2 might be converted to 10-formyl-THF-d1 (loss of additional deuterium) and 
ultimately to methionine-d1. However, these scenarios result in methionine-d2 or methionine-
d1 rather than methionine-d3 and therefore, do not confound our analysis of methionine-d3 and 
its downstream metabolites. 
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Participants and Methods 
A. Participants and Study Design   
A long-term randomized controlled feeding study was carried out among women in different 
reproductive states, as described by Yan et al.18 Briefly, healthy non-pregnant, lactating, and 
third-trimester pregnant women were recruited from the Ithaca, NY area and assessed for 
eligibility using a blood chemistry profile, complete blood count, and health history 
questionnaire. Exclusion criteria included chronic disease, alcohol or tobacco use, and 
indication of liver, kidney, or pregnancy complications.18 Eligible participants (pregnant 
n=26, non-pregnant n=21, lactating n=28) consumed the study diet18 for 10-12 weeks, which 
provided 380 mg choline/d and either 100 or 550 mg choline/d from supplemental choline 
chloride (Balchem). In addition, all participants consumed a daily prenatal multivitamin 
(Pregnancy Plus; Fairhaven Health, LLC) containing 600 µg folic acid, a daily 
docasahexanoic acid supplement (200 mg, Neuromins; Nature’s Way), and a thrice-weekly 
potassium and magnesium supplement (General Nutrition Corp). During study weeks 6-10 
(lactating women) or 6-12 (pregnant and non-pregnant women), participants consumed 22% 
of their total choline in the form of choline chloride-(trimethyl-d9) (Cambridge Isotope 
Laboratories, 98%). The study was approved by the Institutional Review Boards at Cornell 
University and Cayuga Medical Center and was registered at clinicaltrials.gov as 
NCT01127022. All participants provided informed consent. 
B. Sample Collection and Processing 
Fasting blood (10-h) and breast milk samples were collected and processed as previously 
described.13,18 Briefly, blood was collected into EDTA-coated tubes at baseline and study 
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weeks 3, 6, 9, 10, and 12 and placed on ice immediately. After centrifugation (2200 rpm, 15 
minutes, 4°C), plasma and buffy coat were dispensed into 1.5 µL centrifuge tubes. Similar to 
blood, breast milk samples were placed on ice, processed without delay, and stored at −80°C 
until analysis. One lactating participant provided week 9 samples at week 8. Another provided 
samples at week 9.5 that were used for week 9 measurements in plasma and week 10 
measurements in breast milk.  
C. Genotyping  
DNA for genotyping was extracted from blood sample buffy coats using the commercially 
available DNeasy Blood and Tissue kit (Qiagan). Genotyping of MTR (dbSNP: rs1805087; 
c.2756 A>G; p.Asp919Gly; RefSeq NG_008959.1; OMIM 156570) and MTRR (dbSNP: 
rs1801394; c.66 A>G; p.Ile22Met; RefSeq NG_008856.1; OMIM 602568), was performed 
using Endpoint Genotyping on a LightCycler480 (Roche) in our facility. Briefly, a 
commercially available mix (Applied Biosystems® TaqMan® Genotyping Master Mix and 
Assay Mix from Life Technologies) utilizing a dual hydrolysis probe with VIC and FAM 
dyes was used to quantify the fluorescence and presence of the variant and familial alleles. 
High fluorescence of VIC or FAM was considered to be homozygous variant or homozygous 
wild type (WT), respectively, while samples with moderate fluorescence in both VIC and 
FAM channels were considered heterozygous. Samples were run in duplicate with in-run 
standards and a negative water control. Cycling conditions were 95°C for 10 minutes, 
followed by 34 cycles of 92°C for 15s and 62°C for 90s.  
 Genotyping of MTHFD1 (dbSNP: rs2236225; c.1958 G>A; p.Arg653Gln; RefSeq 
NT_026437.13; OMIM 172460) and MTHFR (dbSNP: rs1801133; c.677 C>T; p.Ala223Val; 
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RefSeq NT_021937.17; OMIM 607093) was performed by Sanger-DNA genotyping PCR as 
previously described19 in Cornell’s Life Sciences Core Laboratories Center. The forward and 
reverse primers used for MTHFD1 rs2236225 were 5’GCATCTTGAGAGCCCTGAC3’ and 
5’CACTCCAGTGTTTGTCCATG3’, respectively (Invitrogen).20 Cycling condition were 
95°C for 5 min; 35 cycles (95°C for 30 s, 50°C for 30 s, 72°C for 30 s); 72°C for 10 min, and 
4°C hold. The MTHFR forward and reverse primers were 
5’AGGACGGTGCGGTGAGAGTG3’ and 5’TGAAGGAGAAGGTGTCTGCGGGA3’, 
respectively (Invitrogen).21 Cycling conditions were 95°C for 5 min; 30 cycles (95°C for 30 s, 
60°C for 30 s, 72°C for 30s); 72°C for 10 min, 4°C hold. Double-stranded DNA obtained 
from PCR was purified using a commercially available QIAquick PCR Purification kit 
(Qiagen) and sequenced using an Applied Biosystems Automated 3730 DNA analyzer. 
Internal standards for each genotype were included and all results were duplicated.  
D. Enrichment of Choline Metabolites 
Metabolite enrichments of choline-d9, choline-d3, betaine-d9, betaine-d3, and DMG-d6 as well 
as PC-d3, PC-d6, and PC-d9 were measured at study week 9 for plasma and study week 10 for 
breast milk. Enrichments were measured on our TSQ Quantum Access triple quadrupole 
LCMS system (Thermo) operated in positive-ion mode using electrospray ionization as 
previously described.12,17 Internal standards were not added to samples designated for 
enrichment measurements in order to allow for the measurement of isotopic enrichments. 
Enrichments were calculated by dividing the amount of each isotopically labeled choline 
metabolite by the total amount of all isotopomers and multiplying by 100%.  
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E. Enrichment of Methionine-d3 
Week 9 acidified plasma (250 µL) was thawed and 150 µL of 25 mM ammonium acetate 
buffer was added to each sample. Proteins were precipitated with 125 µL of 1 M perchloric 
acid, and samples were centrifuged at 14,000 rpm for 10 min at 4°C. Supernatant was 
transferred to a new 1.5 µL eppendorf tube and neutralized with 90 µL of 10 M ammonium 
hydroxide (final pH ~ 4.5). Neutralized samples were applied to C18 solid-phase extraction 
(SPE) columns (200mg, 3cc, Sep-Pak® Vac, Waters) with a monofunctionally bonded silica 
phase (preconditioned with 1 mL methanol, 750 µL of 0.1N NaOH, and 1 mL H2O) on a 
vacuum manifold (GAST). Milli-Q water (1 mL) was used to wash the samples before elution 
with 1.5 mL of 0.1% formic acid in 85:15 H2O: methanol. Samples were evaporated in a 
speed vacuum and subsequently resuspended in 50 µL water, diluted with 50 µL 
acetonitrile/methanol (1:1, v/v), and centrifuged (20,000 g, 4 °C, 5 min) before injection into 
the LC-MS.  
F. LCMS for Methionine-d3 
Enrichment measurements of methionine-d3 were performed on a Unimate 3000 UPLC 
(Dionex) and Q Exactive-Mass spectromer (QE-MS, Thermo Scientific) in the Locasale 
Laboratory (Savage Hall, Cornell University). Methods were adapted from Kim et al22. The 
purified extracts containing methionine-d3 were injected (5 µL) into an Xbridge amide 
column (100 x 2.1 mm i.d., 3.5 µm; Waters) and separated by elution (in acetonitrile and 10 
mM ammonium acetate and 2.5 mM ammonium hydroxide in water with 3% acetonitrile, pH 
8.6) at a rate of 150µL/min from 0 to 7.9 min and 19 to 20 min, and 180 µL/min from 8 to 
10.6 min. The linear elution gradient was as follows: 0 min, 85% B; 1.5 min, 85% B; 10.6 
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min, 35% B; 12.5 min, 10% B, 14 min, 10% B, 15 min, 85% B, and 20 min, 85% B. All 
solvents were LC-MS grade and purchased from Fisher Scientific. The QE-MS is equipped 
with a HESI probe, and the relevant parameters are as follows: heater temperature, 120 °C; 
sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for positive mode and 
2.5 kV for negative mode. The capillary temperature was set at 320 °C, and the S-lens was 55. 
The maximum injection time (max IT) was 200 ms. Automated gain control (AGC) was 
targeted at 3 × 106 ions and isolation width was 2.0. The QE-MS was operated in positive full 
scan mode with a resolution of 70,000 and a scan range of 70 to 900 m/z and ions were 
monitored at m/z 150.058 and 153.077, for identification of methionine and methionine-d3, 
respectively.  
G. Quantification of Choline Metabolites 
Total choline, betaine, DMG, and PC pool sizes were quantified at baseline and study weeks 
6, 9, and 10 for plasma and urine, and at study week 10 for breast milk on our TSQ Quantum 
Access triple quadrupole LCMS system (Thermo) operated in positive-ion mode using 
electrospray ionization as previously described.12,17 Serum methionine pool sizes were 
quantified at baseline, study week 6, and study end by gas chromatography-mass 
spectrometry.18  
H. Metabolic Flux Calculations 
When an isotopically labeled metabolic precursor is converted to an isotopically labeled 
metabolic product (precursor→ product), the isotopic enrichment percentages of a metabolic 
precursor and a metabolic product, can be calculated by equations 1 and 2, respectively.  
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	"#$%&ℎ()#*+,-./,01, = 345-3-6	7,-./,01,×9::%	345-3-6</=345-3-6	7,-./,01,      (?) 
 	"#$%&ℎ()#*+,16/.A = 345-3-6	7,16/.A×9::%	345-3-6</=345-3-6	7,16/.A           	(B) 
In the present study, plasma choline metabolite pools were at steady state by study week six18, 
when labeled choline was introduced into the study diet. Under conditions of steady state, 
labeled and unlabeled metabolites within a given pool are turned over at the same rate. Thus, 	"#$%&ℎ()#*+,16/.A can be calculated from "#$%&ℎ()#*+,-./,01, given CD*) (the net 
conversion of precursor to product, in µmoles of metabolite product per liter of plasma, over 
the study period) and EFFG	H%I)+,16/.A (the plasma pool size in µmoles of metabolite product 
per liter of plasma) (Equation 3). We used Equation 3 to derive the rate of conversion of 
metabolic precursors  products in µmols/L/study period, over the three-week period of label 
exposure (Equation 4). 
"#$%&ℎ()#*+,16/.A = "#$%&ℎ()#*+,-./,01,×CD*)		EFFG	H%I)+,16/.A	 							 J  
	CD*) = "#$%&ℎ()#*+,16/.A×EFFG	H%I)+,16/.A	"#$%&ℎ()#*+,-./,01, 														 K  
I. Statistical Analysis 
We examined six metabolic outcomes in plasma as primary response variables. These 
outcomes were chosen to reflect partitioning between metabolic pathways (enrichment ratios 
of betaine-d9/PC-d9, PC-d3+6/PC-d9) or flux through metabolic pathways (metabolic flux 
calculations for turnover of betaine → methionine, betaine → DMG, and choline → betaine 
within the study period). A secondary analysis of individual metabolites in plasma, urine, and 
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breast milk was used to support interpretation. 
The effect of genetic variation on choline metabolites was assessed using linear 
models. Heterozygous and homozygous variant individuals were grouped together to examine 
the effect of variant allele presence. Outcomes were modeled as a function of SNP genotype. 
Reproductive status and choline intake group (480 or 930 mg choline/d) were included as 
covariates. A backwards selection was used in which BMI was retained at an α-cutoff of 0.05 
and interactions were retained at an α-cutoff of 0.1. The 0.1 cutoff for interactions was 
selected to ensure that interactions were detected and prevent the interpretation of main 
effects in the presence of an interaction. SNPs with a low presence of the variant allele were 
evaluated for the effect of minor allele presence (a two-level categorical variable for presence 
or absence of minor allele) on each outcome (Table 1). Standard diagnostic methods were 
used to assess model assumptions and the fit of the model to the data. Reported p-values 
include Bonferroni corrections for multiple comparisons. When evaluating the three-way 
interaction in MTHFD1 models, several groups had only one participant, which precluded the 
use of statistical tests for several comparisons. To avoid pair-wise comparisons with such 
groups, for this one genotype, we chose to compare representative individuals to 95% 
confidence intervals (CIs) constructed around groups with adequate sample size. This 
approach did not allow for the determination of statistical significance of these comparisons, 
but was a conservative and statistically valid alternative given the circumstances. In such 
cases, we report whether the representative individual had metabolite enrichment levels 
outside or inside the 95% constructed around groups with adequate n to which we wished to 
draw comparisons. Two lactating participants had choline-d9 enrichment values greater than 2 
standard deviations from the mean and were excluded from the entire analysis. All statistical 
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analysis was performed using the lsmeans package21 in the R statistical programming 
environment, available from CRAN 2014.23 Data are presented as predicted least-squared 
means, unless otherwise noted. Tables and figures show values for every genotype, 
reproductive state, and choline intake group, while data in the text report average over choline 
intake groups when there is not a choline intake by genotype interaction and averages over 
reproductive states when there is not a reproductive state by genotype interaction. 
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Table 1. Genotype distribution (# of participants) between reproductive states and choline 
intake groups.  
    480 mg Choline/d        930 mg Choline/d 
 
# Of Variant Alleles 
 
0    
 
1    
 
2    
 
0    
 
1    
 
2    
MTHFR rs1801133       
Lactating 4 7 1 5 6 1 
Non-Pregnant 3 4 3 6 5 0 
Pregnant 5 8 0 6 5 2 
       
MTR rs1805087       
Lactating 8 4 0 8 4 0 
Non-Pregnant 6 3 1 8 3 0 
Pregnant 10 3 0 8 5 0 
       
 
MTHFD1 rs2236225       
Lactating 4 7 1 1 8 3 
Non-Pregnant 1 7 2 2 8 1 
Pregnant 6 6 1 4 5 4 
       
MTRR rs1801394       
Lactating 6 3 3 3 7 2 
Non-Pregnant 2 6 2 5 3 3 
Pregnant 2 9 2 2 7 4 
Notes: Because of the relatively low prevalence of the variant allele, heterozygous and 
homozygous variant individuals were combined to examine the effect of variant allele 
presence on metabolic outcomes. 
Abbreviations: MTHFD1, methylenetetrahydrofolate dehydrogenase 
methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase; MTHFR, 
methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine 
synthase reductase. 
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Results 
MTHFR (dbSNP: rs1801133; c.677 C>T; p.Ala223Val; RefSeq NT_021937.17)  
Genotype interacted with reproductive state to influence the partitioning of dietary choline 
between betaine synthesis and CDP-PC synthesis (p = 0.02) as well as the metabolic flux of 
choline → betaine (p = 0.01) (Figure 2, Table 2, Supplemental Table 1). Among non-
pregnant women, variant women exhibited a lower betaine-d9/PC-d9 enrichment ratio 
compared to non-variant women (0.8+/-0.03 vs. 0.9+/-0.04; p = 0.01) and a lower turnover of 
choline → betaine (38+/-5 vs. 56+/-5 µM betaine/study period; p = 0.05) (Table 2).  
Table 2. MTHFR rs1801133 genotype alters plasma choline metabolite partitioning and flux.  
MTHFR rs1801133 
480 mg Choline/d 
p-value 
930 mg Choline/d 
p-value 
Wildtype  Variant Wildtype Variant 
 
Betaine-d9/PC-d9  
RS x Gene interaction;  
p = 0.02* 
  
 
  
 
Lactating 0.79 +/- 0.04 0.82 +/- 0.03 > 0.99 0.93 +/- 0.03 0.96 +/- 0.03 > 0.99 
Non-Pregnant 0.87 +/- 0.04 0.73 +/- 0.03 0.01** 1.0 +/- 0.03 0.87 +/- 0.03 0.01** 
Pregnant 0.66 +/- 0.03 0.65 +/- 0.03 > 0.99 0.79 +/- 0.03 0.79 +/- 0.03 > 0.99 
       
Choline → Betaine  
RS x Gene interaction;  
p = 0.01** 
  
 
  
 
Lactating 34 +/- 6 44 +/- 5 0.6 41 +/- 6 51 +/- 5 0.6 
Non-Pregnant 42 +/- 7  24 +/- 5 0.05* 71 +/- 6 52 +/- 6 0.05* 
Pregnant 11 +/- 6 14 +/- 5 > 0.99 18 +/- 5 20 +/- 5 > 0.99 
       
Betaine → DMG   
Main effect; p = 0.04**       
Lactating 4.4 +/- 1.4 6.8 +/- 1.2 0.04** 6.0 +/- 1.3 8.4 +/- 1.2 0.04** 
Non-Pregnant 6.9 +/- 1.4 9.3 +/- 1.2 0.04** 8.5 +/- 1.3 10.9 +/- 1.3 0.04** 
Pregnant 2.8 +/- 1.3 5.1 +/- 1.1 0.04** 4.4 +/- 1.2 6.8 +/- 1.2 0.04** 
Notes: Values are least-squared means +/- standard errors. Betaine-d9/PC-d9 values are ratios, 
choline → betaine values are in µM betaine/study period, and betaine → DMG values are in 
µM DMG/study period. p-values represent the highest order interaction or main effect.  
Abbreviations: DMG, dimethylglycine, MTHFR, methylenetetrahydrofolate reductase; PC, 
phosphatidylcholine; RS, reproductive state. 
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  Notably, non-pregnant variant women in the higher choline intake group (930 mg/d) 
exhibited metabolic profiles reminiscent of non-pregnant non-variant women at the lower 
(recommended) choline intake (Table 3). Specifically, differences in betaine-d9/PC-d9 
enrichment ratios and turnover of choline → betaine were not observed between variants in 
the higher intake group and non-variants in the lower intake group (p > 0.99) (Table 3). 
Table 3. Comparison of plasma betaine-d9/PC-d9 partitioning and choline → betaine turnover 
between non-pregnant MTHFR rs1801133 and MTR rs1805087 “non-risk” genotype women 
consuming 480 mg choline/d and “risk” genotype women consuming 930 mg choline/d.  
Non-Pregnant 
480 mg Choline/d 
“Risk” Genotype 
930 mg Choline/d 
“Non-Risk” Genotype 
 
p-value 
MTHFR rs1801133 Non-Variant Variant  
Betaine-d9/PC-d9  0.87 +/- 0.04 0.87 +/- 0.03 > 0.99 
Choline → Betaine  42 +/- 7   52 +/- 6 > 0.99 
    
MTR rs1805087 Variant Non-Variant  
Betaine-d9/PC-d9 0.86 +/- 0.04 0.90 +/- 0.03 > 0.99 
Notes: Values are least-squared means +/- standard errors. Betaine-d9/PC-d9 values are ratios, 
and choline → betaine values are in µM betaine/study period.  
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; 
PC, phosphatidylcholine; RS, reproductive state. 
 
Finally, across reproductive states, variant women exhibited a greater flux of betaine 
→ DMG within the study period than non-variant women (7.9+/-0.7 vs. 5.5+/-0.9 µM DMG/study 
period; p = 0.04) (Figure 2, Table 2).  
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Figure 2. Effect of MTHFR 
(dbSNP: rs1801133; c.677 C>T; 
p.Ala223Val; RefSeq 
NT_021937.17) genotype on the 
metabolic flux and partitioning of 
plasma choline metabolites. 
 30 
 
MTR rs1805087 (dbSNP: rs1805087; c.2756 A>G; p.Asp919Gly; RefSeq NG_008959.1) 
MTR non-variant women exhibited metabolic profiles similar to women with the MTHFR 
“risk” genotype.  
First, genotype had a near-significant interaction with reproductive state to influence 
the partitioning of dietary choline between betaine synthesis and CDP-PC synthesis (p = 0.06) 
(Figure 3, Table 4). Though multiple comparisons diminished significance, non-pregnant non-
variant women exhibited a lower betaine-d9/PC-d9 enrichment ratio as compared to non-
pregnant variant women (0.8+/-0.03 vs. 0.9+/-0.04; p = 0.07) (Figure 3, Table 4). 
Secondly, genotype interacted with reproductive state and choline intake to influence 
the flux of choline → betaine (p = 0.008) (Figure 3, Table 4). Genotypic differences were not 
observed in the lower choline intake group. However, within the higher choline intake group, 
non-pregnant non-variant women exhibited a lower flux of choline  betaine than non-
pregnant variant women (50.5+/-5 vs. 94+/-9 µM betaine/study period; p = 0.0008) (Figure 3, 
Table 4). Furthermore, different responses to increased choline intake were detected between 
variant and non-variant women. While non-pregnant non-variant women did not display 
differences in choline → betaine turnover as a function of choline intake, non-pregnant variant 
women used more dietary choline for betaine synthesis in the higher intake group as 
compared to the lower intake group (94+/-9 vs. 23+/-7 µM betaine/study period; p = 5.8x10-7) 
(Table 5). Like the MTHFR “risk” genotype, non-pregnant women without the MTR variant 
in the higher choline intake (930 mg/d) exhibited betaine-d9/PC-d9 enrichment ratios 
reminiscent of MTR variant women in the lower (recommended) intake group (p > 0.99) 
(Table 3). 
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Figure 3. Effect of MTR (dbSNP: 
rs1805087; c.2756 A>G; 
p.Asp919Gly; RefSeq 
NG_008959.1) genotype on the 
metabolic flux and partitioning of 
plasma choline metabolites. 
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Table 4. MTR rs1805087 genotype alters plasma choline metabolite partitioning and flux.  
MTR rs1805087 
480 mg Choline/d 
p-value 
930 mg Choline/d 
p-value 
Wildtype  Variant Wildtype Variant 
 
Betaine-d9/PC-d9  
RS x Gene 
interaction;  
p = 0.06 
  
 
  
 
Lactating 0.81 +/- 0.03 0.80 +/- 0.04 > 0.99 0.96 +/- 0.03 0.95 +/- 0.04 > 0.99 
Non-Pregnant 0.74 +/- 0.03 0.86 +/- 0.04    0.07 0.90 +/- 0.03 1.01 +/- 0.04    0.07 
Pregnant 0.65 +/- 0.03 0.63 +/- 0.04 > 0.99 0.81 +/-0.03 0.78 +/- 0.04 > 0.99 
       
Choline → 
Betaine  
3-way interaction; 
 p = 0.008** 
  
 
  
 
Lactating 41 +/- 5 40 +/- 7 > 0.99 46 +/- 5 48 +/- 7 > 0.99 
Non-Pregnant 33 +/- 6  23 +/- 7 > 0.99 50 +/- 5 94 +/- 9 < 0.001*** 
Pregnant 12 +/- 5 16 +/- 9 > 0.99 19 +/- 5 18 +/- 7 > 0.99 
       
Betaine → 
Methionine  
Cho x Gene 
interaction;  
p = 0.001*** 
      
Lactating 1.31 +/- 0.09 1.54 +/- 0.11   0.1 1.44 +/- 0.09 1.18 +/- 0.11    0.05* 
Non-Pregnant 1.42 +/- 0.10 1.65 +/- 0.11   0.1 1.76 +/- 0.09 1.49 +/- 0.11   0.05* 
Pregnant 1.79 +/- 0.08 2.02 +/- 0.11   0.1 2.29 +/- 0.09 2.03 +/- 0.10 0.05* 
Notes: Values are least-squared means +/- standard errors. Betaine-d9/PC-d9 values are ratios, 
choline → betaine values are in µM betaine/study period, and betaine → methionine values 
are in µM methionine/study period. p-values represent the highest order interaction or main 
effect. Significance at an α-cutoff of: *0.05, **0.01, ***0.001.  
Abbreviations: Cho, choline intake; MTR, methionine synthase; PC, phosphatidylcholine; 
RS, reproductive state. 
Finally, genotype interacted with choline intake to influence the metabolic flux of 
betaine → methionine (p = 0.001). MTR non-variant women and MTR variant women again 
displayed different responses to increased choline intake. Non-variant women in the higher 
intake group exhibited a greater turnover of betaine → methionine (1.8+/-0.06 µM 
methionine/study period) as compared to MTR non-variant women in the lower intake group 
(1.5+/-0.06 µM methionine/study period; p = 0.0008), as well as compared to variant women in 
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the higher intake group (1.6+/-0.08 µM methionine/study period; p = 0.05) (Figure 3, Tables 4 
and 5). Conversely, variant women did not display differences in betaine  methionine 
turnover as a function of choline intake (p = 0.6).  
Table 5. Comparison of choline  betaine and betaine  methionine turnover between 
choline intake groups among MTR rs1805087 variant and non-variant women.  
MTR rs1805087 480 mg Choline/d 930 mg Choline/d 
 
p-value 
 
Choline → Betaine    
Non-Pregnant Wildtype 33 +/- 6 50 +/- 5 > 0.99 
Non-Pregnant Variant 23 +/- 7 94 +/- 9 < 0.001***  
    
Betaine → Methionine    
Wildtype 1.5 +/- 0.06  1.8 +/- 0.06 < 0.001***  
Variant 1.7 +/- 0.08 1.6 +/- 0.08   0.6 
Notes: Values are least-squared means +/- standard errors in µM product/study period. 
Significance at an α-cutoff of: *0.05, **0.01, ***0.001.  
Abbreviations: MTR, methionine synthase. 
MTRR rs1801394 (dbSNP: rs1801394; c.66 A>G; p.Ile22Met; RefSeq NG_008856.1) 
MTRR genotype interacted with reproductive state and choline intake to influence the 
metabolic flux of choline → betaine (p = 0.07) (Figure 4, Table 6). While genotypic 
differences were not detected within choline intake groups (p > 0.16), a differential response 
to choline intake was observed among non-pregnant women with and without the variant, 
similar to MTR “risk” genotype carriers. Specifically, while differences in choline → betaine 
were not observed as a function of choline intake among those without the variant (p > 0.99), 
those with the variant had a greater turnover of choline → betaine in the higher intake group 
as compared to the lower intake group (73+/-6 vs. 49+/-7; p = 6x10-6) (Tables 6 and 7).  
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Figure 4. Effect of MTRR (dbSNP: rs1801394; c.66 A>G; p.Ile22Met; RefSeq NG_008856.1) 
genotype on the metabolic flux and partitioning of plasma choline metabolites. 
Table 6. The effect of MTRR rs1801394 genotype on the metabolic flux of choline → betaine 
MTRR r18011394 
480 mg Choline/d 
p-value 
930 mg Choline/d 
p-value Non-
Variant  Variant 
Non-
Variant Variant 
 
Choline → Betaine  
3-way interaction; p = 0.07 
      
Lactating 44 +-7 38 +/-7 > 0.99 49 +/- 9 46  +/- 5 > 0.99 
Non-Pregnant 48 +/-11 25 +/-6 0.8 49 +/- 7 73 +/- 7 0.2 
Pregnant 14 +/- 11 13 +/- 5 > 0.99 16 +/- 11 19 +/- 5 > 0.99 
Notes: Values are least-squared means +/- standard errors in µM betaine/study period.  
Abbreviations: MTR, methionine synthase. 
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Table 7. Comparison of choline → betaine turnover between choline intake groups among 
MTRR rs1801394 variant and non-variant women.  
MTRR r18011394 
Choline → Betaine 
480 mg Choline/d 930 mg Choline/d 
 
p-value 
 
Variant    
Lactating 38 +/-7 46  +/- 5 > 0.99 
Non-Pregnant 25 +/-6 73 +/- 7 < 0.001*** 
Pregnant 13 +/- 5 19 +/- 5 > 0.99 
    
Non-Variant    
Lactating 44 +-7 49 +/- 9 > 0.99 
Non-Pregnant 48 +/-11 49 +/- 7 > 0.99 
Pregnant 14 +/- 11 16 +/- 11 > 0.99 
Notes: Values are least-squared means +/- standard errors in µM betaine/study period. 
Significance at an α-cutoff of: *0.05, **0.01, ***0.001. 
Abbreviations: MTR, methionine synthase. 
MTHFD1 (dbSNP: rs2236225; c.1958 G>A; p.Arg653Gln; RefSeq NT_026437.13)  
Much like women with the MTHFR and MTR “risk” genotypes, the MTHFD1 variant 
influenced the partitioning of dietary choline between the CDP-choline pathway and betaine 
synthesis.  
Genotype interacted with reproductive state and choline intake to influence 
enrichment of betaine-d9/PC-d9 (p = 0.01) (Figure 5, Table 8). Among non-pregnant women 
in the lower intake group, variant women had a betaine-d9/PC-d9 enrichment ratio well below 
that of the representative non-variant individual (variant least-squares mean: 0.73, non-
variant least-squares mean: 1.07); importantly, the variant’s 95% CI (0.66 - 0.79) did not 
include the non-variant (1.07) (Table 8). Genotypic differences were not observed within the 
higher choline intake group (p > 0.99) (Figure 5, Table 8). However, non-pregnant and 
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lactating variant women exhibited higher (p < 0.003) betaine-d9/PC-d9 enrichment ratios in the 
higher intake group (0.96+/-0.03 and 0.96+/-0.03, respectively) than in the lower intake group 
(0.73+/-0.03 and 0.79+/-0.03, respectively) (Table 9). 
Figure 5. Effect of MTHFD1 (dbSNP: rs2236225; c.1958 G>A; p.Arg653Gln; RefSeq 
NT_026437.13) genotype on the metabolic partitioning of plasma choline metabolites. 
Furthermore, within the higher intake group, both non-pregnant and lactating women 
with the variant exhibited a greater betaine-d9/PC-d9 enrichment ratio (both 0.96+/-0.03) than 
variant pregnant women (0.74+/-0.03; p < 0.001).  Though non-pregnant and lactating women 
with the variant (both 0.96+/-0.03) did not differ (p = 0.2) from non-variant non-pregnant 
women (0.83+/-0/05) or the representative non-variant woman (0.93).   
Genotype also interacted with reproductive state and choline intake to influence the 
partitioning of dietary choline between PEMT-PC (PC-d3+6) and CDP-PC (PC-d9) (p = 
0.0001) (Figure 5, Table 8). Among non-pregnant women consuming the lower choline 
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intake, variants had a PC-d3+6/PC-d9 enrichment ratio below that of the non-variant individual 
(variant least-squares mean: 0.24+/-0.02, non-variant least-squares mean: 0.31); importantly, 
the variant’s 95% CI (0.21–0.27) did not include the non-variant (0.19) (Figure 5). Among 
lactating women consuming the higher choline intake, variants had a PC-d3+6/PC-d9 
enrichment ratio nearly double that of the non-variant individual (0.36+/-0.01 vs. 0.19); 
importantly, the variant’s 95% CI (0.34–0.39) did not include the non-variant (0.19) (Figure 
5, Table 8).  
Table 8. MTHFD1 r2236225 genotype alters plasma choline metabolite partitioning.  
MTHFD1 
rs2236225 
480 mg Choline/d 
p-value 
930 mg Choline/d 
p-value Non-
Variant  Variant 
Non-
Variant Variant 
 
Betaine-d9/PC-d9  
3-way interaction;  
p = 0.01** 
  
 
  
 
Lactating 0.81 +/- 0.05 0.79 +/- 0.03 > 0.99 0.93 NA 0.96 +/- 0.03 in CI 
Non-Pregnant 1.07 NA 0.73 +/- 0.03 ɸ 0.91 +/- 0.07 0.96 +/- 0.03 > 0.99    
Pregnant 0.69 +/- 0.04 0.67 +/- 0.04 > 0.99 0.83 +/-0.05 0.74 +/- 0.03 > 0.99 
       
PC-d3+6/PC-d9  
3-way interaction; 
 p = 0.0001*** 
      
Lactating 0.31 +/- 0.02 0.24 +/- 0.02 0.2 0.19 NA 0.36 +/- 0.01 ɸ 
Non-Pregnant 0.33 NA 0.28 +/- 0.02 ɸ    0.32 +/- 0.03 0.38 +/- 0.02 > 0.99    
Pregnant 0.24 +/- 0.02 0.26 +/- 0.02 > 0.99 0.36 +/- 0.02 0.31 +/- 0.02 > 0.99 
Notes: Values are ratios as least-squared means +/- standard errors. NA signifies a single 
participant. ɸ signifies that the least-square mean of the representative individual falls outside 
the 95% confidence interval (CI) of the comparing group. p-values represent the highest order 
interaction or main effect. Significance at an α-cutoff of: *0.05, **0.01, ***0.001. 
Abbreviations: MTHFD1, methylenetetrahydrofolate dehydrogenase methenyltetrahydro-
folate cyclohydrolase-formyltetrahydrofolate synthetase; PC, phosphatidylcholine. 
In addition, non-pregnant and lactating women with the variant and non-variant 
pregnant women exhibited increased PC-d3+6/PC-d9 as a function of choline intake, displaying 
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a greater PC-d3+6/PC-d9 enrichment ratio at the higher choline intake as compared to the lower 
intake (NP variant: 0.38+/-0.02 vs. 0.28+/-0.02; p = 0.0002) (lactating variant: 0.36+/-0.01 vs. 
0.24+/-0.02; p = 3x10-6) (pregnant non-variant: 0.36+/-0.02 vs. 0.24+/-0.02; p = 0.002) (Table 9). 
Pregnant women with the variant also exhibited a greater PC-d3+6/PC-d9 enrichment ratio in 
the higher choline intake group as compared to the lower intake group, but this difference was 
no longer significant after adjusting for multiple comparisons (0.31+/-0.02 vs. 0.26+/-0.02; p = 
0.2) (Table 9) 
Table 9. Comparison of betaine  methionine turnover between choline intake groups 
among MTHFD1 rs2236225 variant and non-variant women.  
MTHFD1 rs2236225 
Variant 
480 mg Choline/d 930 mg Choline/d 
 
p-value 
 
Betaine-d9/PC-d9    
Lactating 0.79 +/- 0.03 0.96 +/- 0.03  0.003**  
Non-Pregnant 0.73 +/- 0.03 0.96 +/- 0.03 < 0.001*** 
Pregnant 0.67 +/- 0.04 0.74 +/- 0.03 > 0.99 
    
PC-d3+6/PC-d9    
Lactating 0.24 +/- 0.02 0.36 +/- 0.01 < 0.001*** 
Non-Pregnant 0.28 +/- 0.02 0.38 +/- 0.02 < 0.001***  
Pregnant 0.26 +/- 0.02 0.31 +/- 0.02 0.2   
Notes: Values are least-squared means +/- standard errors in ratios. Significance at an α-cutoff 
of: *0.05, **0.01, ***0.001. 
Abbreviations: MTHFD1, methylenetetrahydrofolate dehydrogenase methenyltetrahydro 
folate cyclohydrolase-formyltetrahydrofolate synthetase; PC, phosphatidylcholine. 
Discussion 
The present study is one of few to explore gene by nutrient interactions using stable isotope 
methodology, particularly within the context of a controlled feeding study. The use of an 
isotope label allows for the detection of dynamic changes in metabolite flux, providing an 
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advantage over commonly used static measures, which do not reflect kinetic changes.24 In 
fact, Zeisel and colleagues found that plasma concentrations of choline, betaine, and PC did 
not correlate with clinical signs of choline deficiency in humans deprived of choline.25 
Conversely, although our post-hoc design allowed us the benefit of a controlled environment, 
the original study did not consider genotype during study enrollment, leading to unequal 
genotype distribution that lessened our ability to evaluate pair-wise comparisons within some 
higher order interactions. To address this limitation, and avoid over-interpretation of any 
single comparison with a small sample size, we focused on the identification of broad patterns 
across genes and, metabolites, and tissues that arose from many separate comparisons. This 
approach also mitigates the effect of myriad unexamined genetic factors that may be 
unequally distributed within the study population. Overall, several themes common to “risk” 
genotypes emerged from our data: 
Variants impairing folate enzymes increase the use of dietary choline for phosphatidylcholine 
biosynthesis  
Adequate PC is critical for the structural integrity of cell membranes and cell survival. Both 
the CDP-choline pathway, which uses choline as a substrate, and the PEMT-PC pathway, 
which uses SAM as a methyl donor, have a high metabolic priority. Indeed one of the primary 
uses of SAM is for PEMT-PC-synthesis.26 Given that PEMT-PC comprises a substantial 
portion of cellular PC pools (~30% based on data from rat liver extracts),27 impairments in 
folate-dependent SAM synthesis may decrease the contribution of folate-derived methyl 
groups for cellular PC production and increase the metabolic burden on choline-dependent PC 
synthesis. Our results, described below, support this notion by demonstrating that women 
with common genetic variants (MTHFR rs1801133, MTR rs1805087 wildtype, and MTHFD1 
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rs2236225) impairing folate-dependent enzymes display increased use of dietary choline for 
PC synthesis, primarily through the CDP-choline pathway.  
MTHFR rs18011133 
The MTHFR rs1801133 variant encodes a thermolabile enzyme with reduced capacity to bind 
its cofactor, FAD.28 This translates to impaired production of 5-methylTHF, the substrate for 
the folate-dependent remethylation of homocysteine to methionine. Under conditions of folate 
deprivation, the variant is associated with decreased folate status and increased use of the 
choline derivative betaine for methyl donation.17 Our data extend these findings to include 
women consuming a high folate diet.  
Women with the rs1801133 variant used more betaine as a methyl donor, as indicated 
by a greater turnover of betaine → DMG within the study period. Notably, despite the 
increased turnover of betaine, non-pregnant variant women preferentially partitioned choline 
to the CDP-choline pathway at the expense of betaine synthesis, as indicated by decreased 
turnover of choline → betaine and a lower betaine-d9/PC-d9 enrichment ratio (Figure 2, 
Table 2). The enhanced partitioning of choline to the CDP-choline pathway despite greater 
use of betaine as a methyl donor may be a response to impaired PC synthesis via the PEMT 
pathway, which is dependent upon folate-derived SAM. Although choline-derived methyl 
groups can also be used for SAM synthesis, SAM is used for many different reactions in the 
cell while the CDP-choline pathway is a more direct method of PC production. Among non-
pregnant variant women, higher choline intakes (930 mg/d) restored the rate of conversion of 
choline → betaine and the partitioning between betaine and the CDP-choline pathway to 
levels observed among non-variant women in the 480 mg choline/d group (Figure 2, Table 
3). Given the low presence of homozygous variants within our sample, these findings largely 
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reflect the effect of one copy of the variant, and the burden on dietary choline for PC 
synthesis may be further compounded in women with two copies of the variant. 
MTR rs1805087 
MTR catalyzes the folate-dependent conversion of homocysteine to methionine.29 The MTR 
rs1805087 variant encodes an aspartate to glycine amino acid change located in the region of 
the enzyme that binds accessory proteins to facilitate the regeneration of the active enzyme 
when oxidized.30 The variant has been associated with decreased plasma homocysteine 
concentration, indicating it may provide a gain of function (i.e. an increased use of folate-
derived methyl groups for the remethylation of homocysteine to methionine).31,32 Thus, 
although the variant has been associated with disease risk,33,34 within the context of choline 
requirement, the wildtype genotype may constitute a “risk” genotype” given the 
comparatively reduced efficiency of folate-dependent homocysteine remethylation. 
Indeed, our findings for the MTR wildtype genotype support this notion and parallel 
those observed with the MTHFR rs1801133 “risk” genotype, indicating a prioritization of 
dietary choline for PC production when folate-dependent SAM synthesis is impaired. 
Specifically, within the higher choline intake group, non-pregnant women with the MTR 
wildtype “risk” genotype partitioned more choline to the CDP-choline pathway at the expense 
of betaine synthesis, as indicated by a decreased turnover of choline  betaine, and a lower 
betaine-d9/PC-d9 enrichment ratio, as compared to MTR variant women (Figure 3, Table 4).  
Even under conditions of folate adequacy, non-pregnant MTR wildtype women displayed an 
increased use of choline as a methyl donor in response to increased dietary choline, as 
indicated by a greater turnover of betaine → methionine (Figure 3, Table 5). In contrast, 
although non-pregnant MTR variant women exhibited an increased flux of choline → betaine 
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with increased choline intake, they did not increase their use of betaine as a methyl donor, 
instead accumulating plasma betaine, which manifested as larger plasma betaine pools among 
variant women as compared to wildtype women in the higher choline intake group (53+/-5 vs. 
35+/-3 µM betaine; p = 0.003). This supports the notion that non-pregnant women with the 
variant may have a decreased need for dietary choline as compared to wildtype women in 
conditions of folate adequacy. In addition, women with the MTR wildtype “risk” genotype 
may benefit from choline intakes exceeding current recommendation given the restoration of 
choline partitioning among wildtype women in the higher choline intake group to levels 
observed in the MTR variant women in the lower intake group (Figure 3, Table 3).  
MTRR rs1801394 
Methionine Synthase Reductase (MTRR) is a diflavin enzyme that participates in methionine 
biosynthesis by regenerating the oxidized MTR-Co(II) to active enzyme via a reductive 
methylation with S-adenosylmethionine35. Some, but not all, studies have identified moderate 
associations between the MTRR rs1801394 variant and neural tube defects36 and elevated 
homocysteine concentrations, particularly in the presence of the MTHFR rs1801133 variant 
and low vitamin B12 status.37 Due to power limitations, we did not consider vitamin B12 
status or MTHFR rs1801133 genotype and therefore may not have fully captured its metabolic 
consequences. We did, however, detect a different response among variant individuals to 
increased choline intake (Figure 4, Table 7). Although non-variants did not use additional 
choline for betaine synthesis, variants exhibited increased turnover of choline → betaine in 
the higher choline intake group, suggesting that variants may have a greater need for choline 
derived methyl groups. 
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MTHFD1 rs2236225 
The MTHFD1 rs2236225 polymorphism encodes a thermolabile enzyme with a ~50% 
reduction in enzymatic activity38 and appears to favor thymidylate biosynthesis at the expense 
of folate-dependent homocysteine remethylation. The variant also increases susceptibility to 
choline deficiency among premenopausal women deprived of choline.7 Our findings suggest 
that the MTHFD1 rs2236225 variant may increase susceptibility to choline and PC 
inadequacy, even at choline intakes that align with current recommendations. Non-pregnant 
variant women consuming 480 mg choline/d preferentially partitioned choline towards the 
CDP-choline pathway at the expense of betaine synthesis (i.e., a lower betaine-d9/PC-d9 
enrichment ratio was observed among variant women as compared to the representative non-
variant woman), which signifies a strain on cellular PC production (Figure 5). In addition, 
pregnant and lactating women exhibited increased CDP-PC synthesis across genotypes at the 
lower intake level, indicating a greater need for choline-dependent PC production during these 
reproductive states (Figure 5).  
Nonetheless, our data showed favorable metabolic changes among non-pregnant and 
lactating women with the MTHFD1 rs2236225 variant when choline intake exceeded current 
recommendations. Both non-pregnant and lactating variant women displayed greater betaine-
d9/PC-d9, suggesting that increased dietary choline among variant carriers may decrease strain 
on PC production capacity (Figure 5, Table 8). Notably, at the higher choline intake level, 
non-variant women at all three reproductive states, as well non-pregnant and lactating women 
with the variant, exhibited similar partitioning between betaine and the CDP-choline pathway 
(Figure 5). This suggests that intakes of 930 mg/d are sufficient to restore partitioning among 
pregnant and lactating women without the variant to levels observed in non-pregnant women, 
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as well as partitioning among non-pregnant and lactating women with the variant to levels 
observed among non-variants. Variant pregnant women, on the other hand, exhibited 
preferential partitioning to the CDP-choline pathway even at the higher choline intake level, 
indicating that pregnant women with the variant may have a comparatively greater 
requirement for dietary choline in order to support PC production. 
A second favorable metabolic change observed among variant non-pregnant and 
lactating women consuming higher choline intakes was the greater relative presence of 
PEMT-derived metabolites in circulation. Both non-pregnant and lactating women with the 
variant exhibited greater PC-d3+6/PC-d9, indicating that a greater portion of the dietary choline 
converted to PC was synthesized through the PEMT-PC pathway (Figure 5, Tables 8 and 9). 
In addition, among lactating women, higher choline consumption yielded greater enrichments 
of favorable PEMT-derived metabolites in plasma and breast milk compared to the 
representative non-variant lactating woman in the higher intake group, as well as compared to 
lactating variant women in the lower intake group (Figure 6; Tables 10 and 11). PEMT-PC 
and its lipid derivatives are enriched with long-chain polyunsaturated fatty acids such as 
DHA,39 which beneficially influence brain development.40 Improved plasma and breast milk 
PEMT metabolite composition may therefore provide an evolutionary basis for the high 
prevalence of this SNP in populations consuming high-choline diets despite its association 
with increased disease risk and evidence for negative selection in low choline environments.41 
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Table 10. MTHFD1 r2236225 genotype alters plasma and breast milk choline metabolite 
partitioning among lactating women.  
MTHFD1 r2236225 
480 mg Choline/d 
In 
CI? 
930 mg Choline/d 
In 
CI? 
Non-
Variant  Variant 
Non-
Variant Variant 
 
Plasma       
PC-d3/PC-d9 0.29 (0.26-0.32) 0.23 (0.21-0.25) No 0.18 (NA) 0.33 (0.31-0.36) No 
Choline-d3/Choline-d9 0.32 (0.27-0.36) 0.24 (0.22-0.26) No 0.18 (NA) 0.34 (0.30-0.36) ɸ 
Betaine-d3/Betaine-d9 0.25 (0.20-0.30) 0.18 (0.17-0.20) No 0.09 (NA) 0.23 (0.20-0.25) No 
       
Breast Milk       
PC-d3/PC-d9 0.23 (0.18-0.29) 0.18 (0.17-0.19) Yes X 0.13 (NA) 0.23 (0.21-0.26) No 
Choline-d3/Choline-d9 0.26 (0.24-0.28) 0.22 (0.20-0.25) Yes* 0.14 (NA) 0.29 (0.26-0.34) No 
Betaine-d3/Betaine-d9 0.80 (0.63-0.97) 0.51 (0.37-0.66) Yes* 0.33 (NA) 0.71 (0.61-0.80) No 
Notes: X Student’s t-test failed to reject the null hypothesis * Significantly different by 
student’s t-test. Values are group means and (95% CIs). Not available (NA) signifies a single 
participant. ɸ signifies that the least-square mean of the representative individual falls outside 
the 95% confidence interval of the comparing group. Although non-overlapping confidence 
intervals indicate a significant difference, overlapping confidence intervals do not necessarily 
exclude a significant difference. In cases where confidence intervals were overlapping, a 
student’s t-test was performed using the Welch–Satterthwaite equation to calculate degrees of 
freedom. 
Abbreviations: CI, confidence interval; MTHFD1, methylenetetrahydrofolate dehydrogenase 
methenyltetrahydro folate cyclohydrolase-formyltetrahydrofolate synthetase; PC, 
phosphatidylcholine. 
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Figure 6. Effect of 
MTHFD1 (dbSNP: 
rs2236225; c.1958 
G>A; p.Arg653Gln; 
RefSeq NT_026437.13) 
genotype on enrichment 
ratios of PEMT-derived d3 
choline metabolites to 
dietary choline-derived d9 
choline metabolites. 
Presented as group 
means and 95% 
confidence intervals. 
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Table 11. Comparison of d3/d9 metabolite partitioning between choline intake groups among 
MTHFD1 rs2236225 lactating women consuming 480 or 930 mg choline/d.  
MTHFD1 rs2236225 
Variant 
480 mg Choline/d 930 mg Choline/d 
 
In CI? 
 
Plasma    
PC-d3/PC-d9 0.23 (0.21-0.25) 0.33 (0.31-0.36) No 
Choline-d3/Choline-d9 0.24 (0.22-0.26) 0.34 (0.30-0.36) No 
Betaine-d3/Betaine-d9 0.18 (0.17-0.20) 0.23 (0.20-0.25) No 
    
Breast Milk    
PC-d3/PC-d9 0.18 (0.17-0.19) 0.23 (0.21-0.26) No 
Choline-d3/Choline-d9 0.22 (0.20-0.25) 0.29 (0.26-0.34) No 
Betaine-d3/Betaine-d9 0.51 (0.37-0.66) 0.71 (0.61-0.80) Yes* 
Notes: *Significantly different by student’s t-test. Values are group means of ratios with 95% 
confidence intervals. In cases where confidence intervals were overlapping, a student’s t-test 
was performed using the Welch–Satterthwaite equation to calculate degrees of freedom. 
Abbreviations: CI, confidence interval; MTHFD1, methylenetetrahydrofolate dehydrogenase 
methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase; PC, 
phosphatidylcholine. 
Pregnant women exhibit few alterations in choline metabolism as a function of SNPS 
impairing folate enzymes 
Given that the demand for choline is higher during pregnancy and lactation, and that 
genotypic effects are often more pronounced under conditions of nutrient inadequacy, we 
expected pregnant and lactating women to exhibit greater genotype-specific differences in 
choline partitioning than their non-pregnant counterparts. However, the metabolic flux of 
choline among pregnant women (and in some cases lactating women) was similar across 
genotypes, perhaps because the “risk” genotypes altered choline dynamics in ways that mirror 
changes observed during pregnancy. Thus, the physiological changes that alter choline 
metabolism in pregnancy (and to a lesser extent lactation) seemingly outweigh the effect of 
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genotype in many of the examined polymorphisms and indicate a greater choline requirement 
for this reproductive state as a whole.  
Consideration of genotype in defining choline requirements 
Our results indicate that genotype influences choline dynamics, even at and above the choline 
AI. Women with SNPs that impair folate-mediated methionine biosynthesis (i.e. MTHFR 
rs1801133, MTR rs1805087 wildtype, and MTHFD1 rs2236225) displayed a pattern of 
preferential partitioning of dietary choline to the CDP-choline pathway, despite using more 
betaine for methionine biosynthesis (i.e. MTHFR rs1801133, MTR rs1805087 wildtype). This 
indicates a greater burden on dietary choline for PC synthesis, perhaps due to impaired folate-
dependent PC production through the PEMT pathway. Notably, across these “risk” genotypes, 
increased choline intake appeared to restore dietary choline partitioning between betaine and 
the CDP-choline pathway to levels observed in those without the “risk” allele (Table 3). 
These findings collectively suggest that even in conditions of folate adequacy, women of 
reproductive age with SNPs impairing folate metabolism may benefit from choline intakes 
exceeding current recommendations.  
Conclusions 
In sum, these data provide compelling evidence that common SNPs in folate-metabolizing 
enzymes modulate choline dynamics in women of reproductive age consuming choline and 
folate intakes relevant to the population at large. Carriers of SNPs that alter cellular 
methylation capacity may rely more on choline-dependent PC synthesis as observed among 
MTR rs1805087 wildtype, and MTHFR rs1801133, MTHFD1 rs2236225, and possibly MTRR 
rs1801394, variant women consuming 480 mg choline/d. Choline partitioning was restored 
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with higher choline intakes (930 mg/d). The metabolic strain on choline for PC synthesis may 
be particularly pronounced in the general population as American women consume on 
average 260 mg choline/d, well below the lower study intake level and choline AI42. The 
present findings also suggest that the partitioning of dietary choline between betaine and the 
CDP-choline pathway is a sensitive indicator of subclinical differences in choline 
requirements. These metabolic differences, while not severe enough to present as acute 
muscle or liver pathologies, may have long-term consequences on human health and chronic 
disease. Further studies with greater sample size are needed to confirm these findings and 
identify whether such metabolic differences have clinical implications.  
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Supplemental Information 
Supplemental Table 1. Effect of SNP genotype (p-values) on plasma choline metabolite 
partitioning and flux.  
Notes: Significance at an α-cutoff of: *0.05, **0.01, ***0.001.  
Abbreviations: Cho, choline intake level; DMG, dimethylglycine; G, Gene; PC, 
phosphatidylcholine; RS, reproductive state. 
   Gene  G*RS G*Cho Three-way 
MTHFR rs1801133           
Betaine-d9/PC-d9    0.1 0.022* - - 
PC-d3+6/PC-d9   0.3 - - - 
Choline → Betaine    0.6 0.01* - - 
Betaine → DMG   0.04* - - - 
Betaine → Methionine  0.3 - - - 
MTR rs1805087       
Betaine-d9/PC-d9   0.4 0.06 - - 
PC-d3+6/PC-d9   0.5 - - - 
Choline → Betaine   0.3 0.2 0.04 0.008** 
Betaine → DMG   0.9 - - - 
Betaine → Methionine  0.9 - 0.001*** - 
MTHFD1 rs2236225           
Betaine-d9/PC-d9   0.02 0.7 0.2 0.01** 
PC-d3+6/PC-d9   0.8 0.8 0.08 0.0001*** 
Choline → Betaine  0.2 - - - 
Betaine → DMG   0.4 - - - 
Betaine → Methionine   0.6 - - - 
MTRR rs1801394       
Betaine-d9/PC-d9   0.7 - - - 
PC-d3+6/PC-d9   0.2 - - - 
Choline → Betaine   0.6 0.6 0.05 0.07 
Betaine → DMG   0.96 - - - 
Betaine → Methionine   0.2 - - - 
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CHAPTER 2 
Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism in Young 
Women Consuming Choline Intakes Meeting Current Recommendations* 
Abstract 
Single nucleotide polymorphisms (SNPs) in choline metabolizing genes are associated with 
disease risk and greater susceptibility to organ dysfunction under conditions of dietary choline 
restriction. However, the underlying metabolic signatures of these variants are not well 
characterized and it is unknown whether genotypic differences persist at recommended 
choline intakes. Thus, we sought to determine if common genetic risk factors alter choline 
dynamics in pregnant, lactating, and non-pregnant women consuming choline intakes meeting 
and exceeding current recommendations. Women (n = 75) consumed 480 or 930 mg 
choline/day (22% as a metabolic tracer, choline-d9) for 10–12 weeks in a controlled feeding 
study. Genotyping was performed for eight variant SNPs and genetic differences in metabolic 
flux and partitioning of plasma choline metabolites were evaluated using stable isotope 
methodology. CHKA rs10791957, CHDH rs9001, CHDH rs12676, PEMT rs4646343, PEMT 
rs7946, FMO3 rs2266782, SLC44A1 rs7873937, and SLC44A1 rs3199966 altered the use of 
choline as a methyl donor; CHDH rs9001 and BHMT rs3733890 altered the partitioning of 
dietary choline between betaine and phosphatidylcholine synthesis via the cytidine 
diphosphate (CDP)-choline pathway; and CHKA rs10791957, CHDH rs12676, PEMT 
rs4646343, PEMT rs7946 and SLC44A1 rs7873937 altered the distribution of dietary choline 
between the CDP-choline and phosphatidylethanolamine N-methyltransferase (PEMT) de 
novo pathway. Such metabolic differences may contribute to disease pathogenesis and 
                                                
*Ganz. et al. Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism 
in Young Women Consuming Choline Intakes Meeting Current Recommendations. Int. J. 
Med. Sci. 2017 18(2). 
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prognosis over the long-term. 
Introduction 
Choline is an essential micronutrient with critical roles in a wide-array of physiologic processes 
[1]. As a source of methyl groups, choline supports cellular methylation reactions, including 
genomic methylation, which influences gene expression and DNA stability. Choline also serves 
as the substrate for the formation of acetylcholine, a neurotransmitter and non-neuronal cell-
signaling molecule. Quantitatively, the primary metabolic fate of choline is biosynthesis of 
phosphatidylcholine (PC), the most abundant phospholipid in cell membranes [2]. 
Phosphatidylcholine adequacy is critical for cell membrane integrity and the export of fat from 
the liver by very low density lipoproteins (VLDL) [1]. Choline contributes to PC synthesis 
through two distinct pathways. Either choline can be phosphorylated, entering the cytidine 
diphosphate (CDP)-choline pathway where it is converted directly to PC, or, its methyl groups 
can be used in the triple-methylation of phosphatidylethanolamine (PE) to PC, which occurs by 
the phosphatidylethanolamine N-methyltransferase (PEMT) pathway [3]. This pathway is also 
responsible for endogenous choline production as PC can be produced through the PEMT 
pathway using PE and folate or methionine-derived methyl groups in the absence of dietary 
choline. The efficiency of endogenous choline production varies from person to person, and is 
greater among pre-menopausal women because PEMT is up regulated by estrogen. However, 
choline itself is used to support the PEMT pathway and is considered an essential dietary 
requirement because endogenous production capacity is not enough to support biological 
choline requirements [4–6]. Dietary choline restriction causes acute muscle and liver 
dysfunction and choline must be obtained from the diet to prevent deficiency [7]. However, 
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there is a large inter-individual variation in dietary choline requirement that depends upon 
genetic and physiological factors [4]. 
Considering the critical metabolic and structural roles of choline, it is not surprising that 
genetic variants that alter choline metabolism have been linked to increased risk for acute 
skeletal muscle and liver pathologies under conditions of dietary choline deprivation [8], as 
well as birth defects and other diseases in the general population (Table 1). However, the 
underlying metabolic signatures of these variants are not well characterized, and it is 
unknown whether genotypic differences persist among women meeting choline intake 
recommendations. Moreover, little is known about the effect of gene–nutrient interactions on 
choline metabolism and functional outcomes in reproductive states (i.e., pregnancy and 
lactation) that increase the metabolic use of choline [9]. We have previously shown that 
genetic variants in folate-metabolizing genes are associated with differences in choline 
dynamics and partitioning among women meeting current intake recommendations [9]. In the 
present study, we used isotopically labeled dietary choline to characterize differences in the 
metabolic flux and partitioning of dietary choline among carriers of genetic polymorphisms in 
choline metabolizing enzymes (Figure 1).
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Table 1. Summary of examined SNPs and their connections to disease 
Gene Function SNP Choline Deficiency Risk  Disease Associations References 
CHKA Phosphorylates choline, first step in CDP-choline pathway rs10791957 ↓ risk organ dysfunction * ↓ risk type 2 diabetes [10,11] 
CHDH First step in oxidation of choline to betaine 
rs9001 ↓ risk organ dysfunction ↑ arsenic methylation [10,12] 
rs12676 ↑ risk organ dysfunction ** 
↑ breast cancer risk 
[13,14] ↓ sperm ATP and altered sperm 
motility 
BHMT Converts homocysteine to methionine  using betaine as a methyl donor  rs3733890 - 
↓ breast cancer mortality 
[10,15–18] ↑ orofacial cleft 
↑ spina bifida (mixed results) 
PEMT Uses SAM to triply methylate PE to  form PC (endogenous choline synthesis)  
rs4646343 ↑ risk organ dysfunction 
↑ PEMT expression in adipose 
[19] 
↑ waist to hip ratio 
rs7946 - ↑ Non-alcoholic fatty liver disease [20,21] 
FMO3 Converts TMA to TMAO  rs2266782 - ↑ trimethylaminuria [22] 
SLC44A1 Transports choline across the cellular and mitochondrial membranes 
rs7873937 ↑ risk muscle damage  [10] 
rs3199966 ↑ risk muscle damage  [10] 
* Among women; ** among pre-menopausal women. ↑ increased, ↓ decreased. 
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Figure 1. An overview of the metabolic fate of the isotopically labeled choline-d9 consumed by study participants. SNPs in squared enzymes were 
examined. Choline kinase-α (CHKA) rs10791957; choline dehydrogenase (CHDH) rs9001, CHDH rs12676; betaine homocysteine methyltransferase 
(BHMT) rs3733890; phosphatidylethanolamine N-methyltransferase (PEMT) rs7946, PEMT rs4646343; solute carrier 44A1 (SLC44A1) rs7873937, 
SLC44A1 rs3199966; and flavin monooxygenase isoform 3 (FMO3) rs2266782). 
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Participants and Methods 
A. Participants and Study Design   
This study was a follow-up investigation of a long-term randomized controlled feeding study 
conducted among women of reproductive age by Yan et al. [6]. Healthy third-trimester 
pregnant (n = 26), lactating (n = 28), and non-pregnant (n = 21), women consumed the study 
diet containing 380 mg choline/day, and either 100 or 550 mg choline/day from supplemental 
choline chloride (Balchem) for 10–12 weeks [6]. All participants also consumed a daily 
prenatal multivitamin (Pregnancy Plus; Fairhaven Health, LLC, Bellingham, WA, USA) 
containing 600 µg folic acid, a daily docasahexanoic acid supplement (200 mg, Neuromins; 
Nature’s Way, Perris, CA, USA), and a potassium and magnesium supplement (General 
Nutrition Corp, Pittsburgh, PA, USA) thrice weekly. Beginning at week 6, participants 
consumed 22% of their total choline in the form of choline chloride-(trimethyl-d9) 
(Cambridge Isotope Laboratories, Tewksbury, MA, USA, 98%). Fasting blood (10 h) was 
collected at study baseline and throughout the study and processed as previously described 
[6]. All samples were stored at −80 °C until analysis. The study was approved by the 
Institutional Review Boards at Cornell University and Cayuga Medical Center and was 
registered at clinicaltrials.gov as NCT01127022. All participants provided informed consent. 
B. Genotyping 
DNA was extracted from buffy coat for genotyping of PEMT rs7946, PEMT rs4646343, 
CHDH rs9001, CHDH rs12676, CHKA rs10791957, SLC44A1 rs7873937, SLC44A1 
rs3199966, BHMT rs3733890, and FMO3 rs2266782 SNPs using the Qiagen DNeasy Blood 
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and Tissue on a LightCycler480 (Roche, Indianapolis, IN, USA). Endpoint genotyping was 
carried out as previously described using participant DNA and two commercially available 
products, (Applied Biosystems TaqMan Genotyping Master Mix and Thermo Fisher 
Scientific Assay Mix, Waltham, MA, USA) on a LightCycler 480 (Roche) in our facility [9].   
C. Enrichment of Choline Metabolites 
Choline metabolites were extracted from blood and enrichments of choline-d9, choline-d3, 
betaine-d9, betaine-d3, and DMG-d6 as well as PC-d3, PC-d6, and PC-d9, were measured 
using a TSQ Quantum Access triple quadrupole LCMS system (Thermo) operated in positive-
ion mode using electrospray ionization as previously described in detail [9]. Enrichments of 
methionine-d3 were measured by gas chromatography-mass spectrometry (GC-MS) [9]. 
Enrichment percentages were calculated by dividing the area of each isotopically labeled 
choline metabolite by the total area of all isotopomers and multiplying by 100% (Equation 
(1)). 
!"#$%ℎ'(")*+,-./01,+ = 345(3(6	'()4583$)(	×100%	345(3(6 + >"345(3(6	'()4583$)( (1) 
 
D. Statistical Analysis 
Seven metabolic outcomes in plasma were examined as primary response variables. Two of 
these outcomes were chosen to reflect partitioning between metabolic pathways (enrichment 
ratios of betaine-d9/PC-d9 and PC-d3+6/PC-d9). The other five outcomes were chosen to reflect 
flux through metabolic pathways and included turnover of choline ® betaine, choline ® 
CDP-PC, betaine ® DMG, betaine ® methionine, and choline-derived methionine ® PEMT-
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PC within the study period. Metabolic flux was defined as the rate of turnover of metabolic 
precursors ® products in µmols/L/study period over the three-week period of label exposure 
(Equation (2)), where 	!"#$%ℎ'(")?@/ABC, and !"#$%ℎ'(")?@+CB@D/@ are enrichments 
(percentages) of the product and precursor, and E883	F$G(?@/ABC, is the plasma pool size in 
µmoles of metabolite product per liter of plasma. 
H4)(,B@I/J+@ 	= !"#$%ℎ'(")?@/ABC,×E883	F$G(?@/ABC,	!"#$%ℎ'(")?@+CB@D/@  (2) 
 
The effect of genetic variation on each of these seven outcomes as a function of SNP genotype 
was assessed using linear models. Due to limited variant allele presence within our sample 
(Table 2), heterozygous and homozygous variant individuals were grouped together to examine 
the effect of variant allele presence. Reproductive status, choline intake group (480 or 930 mg 
choline/day), and possible interactions were included as covariates. A backwards selection was 
used in which BMI was retained at an α-cutoff of 0.05 and interactions were retained at an α-
cutoff of 0.1 (the higher interaction cutoff was selected to prevent the interpretation of main 
effects in the presence of interactions). Model assumptions and the fit of the model to the data 
were assessed with standard diagnostic methods. Two lactating participants with choline-d9 
enrichment values greater than 2 standard deviations from the mean were excluded from the 
entire analysis. All statistical analysis was performed using the lsmeans package in the R 
statistical programming environment, available from CRAN 2014 [48]. Data are presented as 
predicted least-squared means, unless otherwise noted. Reported p-values include Bonferroni 
corrections for multiple comparisons and were considered significant at an α-cutoff of 0.05. 
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Results 
A. Genotype Distribution 
The distribution of genotypes within our cohort (n = 75) is depicted in Table 2. Because of the 
relatively low prevalence of the variant allele, heterozygous and homozygous variant 
individuals were combined to examine the effect of variant allele presence on metabolic 
outcomes. The number of participants in each sub-group analysis varies by gene and metabolic 
outcome. For example, if there are no interactions, there are more participants in each group 
because we are comparing all of the women of a certain genotype against all of the women of 
the other. On the other hand, when interactions are present, the groups are stratified by the 
interacting factor (e.g., reproductive status and/or choline intake), which decreases the number 
of participants per group. 
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Table 2. Genotype distribution (# of participants) among reproductive states and choline intake 
groups. 
Group 480 mg Choline/day 930 mg Choline/day 
# Of Variant Alleles 0 1 2 0 1 2 
CHKA rs10791957       
Lactating 2 5 6 2 4 7 
Non-pregnant 2 5 3 2 7 2 
Pregnant 2 6 5 1 3 9 
CHDH rs9001       
Lactating 11 1 1 10 2 1 
Non-pregnant 6 4 0 9 2 0 
Pregnant 10 2 1 10 2 1 
CHDH rs12676       
Lactating 5 7 1 9 3 1 
Non-pregnant 7 1 2 5 6 0 
Pregnant 6 6 1 8 4 1 
BHMT rs3733890       
Lactating 5 6 2 3 8 2 
Non-pregnant 4 6 0 9 1 1 
Pregnant 8 4 1 6 6 1 
PEMT rs4646343       
Lactating 6 4 3 6 6 1 
Non-pregnant 5 5 0 6 4 1 
Pregnant 5 5 3 6 4 3 
PEMT rs7946       
Lactating 2 2 9 2 2 9 
Non-pregnant 2 5 3 3 5 3 
Pregnant 0 6 7 2 3 8 
FMO3 rs2266782       
Lactating 7 5 1 3 8 2 
Non-pregnant 6 3 1 4 4 3 
Pregnant 6 4 3 7 4 1 
SLC44A1 rs7873937       
Lactating 11 2 0 11 2 0 
Non-pregnant 8 2 0 9 2 0 
Pregnant 9 3 1 11 2 0 
SLC44A1 rs3199966       
Lactating 10 3 0 11 2 0 
Non-pregnant 8 2 0 8 3 0 
Pregnant 8 4 1 9 4 0 
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A. CHKA rs10791957 
Genotype influenced the production of PEMT-PC and the partitioning of dietary choline 
between PEMT-PC and CDP-PC (Tables 3 and S1). Specifically, variant women exhibited a 
lower turnover of choline-derived methionine ® PEMT-PC (8840 ± 291 vs. 11512 ± 664 µM 
PC/study period; p = 0.0005) over the study period and tended to have lower PC-d3+6/PC-d9 
enrichment ratios than non-variants (0.30 ± 0.007 vs. 0.33 ± 0.015; p = 0.09) (Table 3, Figure 2). 
Table 3 CHKA rs10791957 genotype alters plasma choline metabolite partitioning and flux.  
Metabolic Outcome WT Variant p-Value 
Choline-Derived Methionine ® PEMT-PC 11512 ± 664 8840 ± 291 0.0005 
PC-d3+6/PC-d9 0.33 ± 0.015 0.30 ± 0.007 0.09 
Notes: Values are least-squared means ± standard errors for each group. PC-
d3+6/PC-d9 values are ratios, choline-derived methionine ® PEMT-PC values are 
in µM PEMT-PC/study period. 
Abbreviations: CHKA, choline kinase-α; PC, phosphatidylcholine; PEMT, 
Phosphatidylethanolamine N-methyltransferase; RS, reproductive state; WT, wildtype. 
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(a) (b) 
Figure 2 Effect of the CHKA rs10791957 variant on the metabolic flux and 
partitioning of dietary choline. (a) Choline-derived methionine ® PEMT-PC flux; (b) 
PC-d3+6/PC-d9 partitioning. 
B. CHDH rs9001 
Genotype interacted with reproductive state to influence the turnover of choline ® CDP-PC (p 
= 0.04) (Table 4, Figure 3a). While differences in choline ® CDP-PC flux were not observed 
among pregnant or non-pregnant women, among lactating women, variants tended to exhibit a 
greater turnover of choline ® CDP-PC as compared to non-variants (3355 ± 295 vs. 2541 ± 167 
µM PC/study period; p = 0.09) (Table 4). 
 
 
 
 
 
CHKA rs10791957
Reproductive State
Main effect; p = 0.0005
Ch
ol
in
e-
De
riv
ed
 M
et
hi
on
in
e 
→
 
PE
M
T-
PC
 F
lu
x
 (µ
M
 P
EM
T-
PC
 / 
St
ud
y P
er
iod
)
Lactating NP Pregnant Lactating NP Pregnant
Reproductive State
Main effect; p = 0.09 
PC
-d
3+
6 /
 P
C-
d 9
 P
ar
tit
io
ni
ng
(E
nr
ich
m
en
t R
at
io)
Lactating NP Pregnant Lactating NP Pregnant
CA & AACC
930 mg choline/day 480 mg choline/day 930 mg choline/day 480 mg choline/day 
 68 
 
Table 4. Comparison of choline ® CDP-PC turnover between genotypes by 
reproductive state 
Metabolic Outcome and Group WT Variant p-Value 
Choline ® CDP-PC    
RS × Gene Interaction; p = 0.04 
Lactating 2542 ± 167 3355 ± 324 0.09 
Non-pregnant 2875 ± 185 2836 ± 295 >0.99 
Pregnant 4279 ± 159 3804 ± 290 0.5 
Notes: Values are least-squared means ± standard errors for each group in µM CDP-
PC/study period. 
Abbreviations: CDP, cytidine diphosphate; PC, phosphatidylcholine; RS, reproductive 
state; WT, wildtype. 
 
 
(a) (b) 
Figure 3. Effect of the CHDH rs9001 variant on the metabolic flux and partitioning 
of dietary choline. (a) Choline ® CDP-PC flux; (b) Betaine-d9/PC-d9 partitioning 
In addition, genotype tended to interact with choline intake to predict betaine-d9/PC-d9 
enrichment (p = 0.07) (Table 5, Figure 3b). Within the lower choline intake group, variant 
women exhibited lower betaine-d9/PC-d9 enrichment ratios than non-variants (0.68 ± 0.03 vs. 
0.77 ± 0.02; p = 0.06) (Table 5). Genotypic differences were not observed among women 
consuming the higher choline intake. 
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Table 5. Comparison of betaine-d9/PC-d9 enrichment ratios between CHDH rs9001 
genotypes by choline intake group.  
Metabolic Outcome and Group WT Variant p-Value 
Betaine-d9/PC-d9    
Cho × Gene Interaction; p = 0.07 
480 mg Choline/day 0.77 ± 0.02 0.68 ± 0.03 0.06 
930 mg Choline/day 0.89 ± 0.02 0.91 ± 0.04 >0.99 
Notes: Values are least-squared means ± standard errors in ratios. 
Abbreviations: CDP, cytidine diphosphate; PC, phosphatidylcholine; RS,  
reproductive state; WT, wildtype. 
C. CHDH rs12676 
Genotype influenced the partitioning of dietary choline between PEMT-PC and CDP-PC 
(Figure 4). Specifically, variant individuals tended to have greater PC-d3+6/PC-d9 enrichment 
ratios as compared to non-variants (0.32 ± 0.009 vs. 0.30 ± 0.008; p = 0.055) (Table 6, Figure 4a). 
Table 6. CHDH rs12676 genotype alters plasma choline metabolite partitioning.  
Metabolic Outcome WT Variant p-Value 
PC-d3+6/PC-d9 0.30 ± 0.008 0.32 ± 0.009 0.055 
Notes: Values are least-squared means ± standard errors in  
ratios. 
Abbreviations: CHDH, choline dehydrogenase; PC,  
phosphatidylcholine; WT, wildtype. 
  
 70 
 
 
(a) (b) 
 
(c) (d) 
Figure 4. Effect of the CHDH rs12676 variant on the metabolic flux and partitioning 
of dietary choline. (a) PC-d3+6/PC-d9 partitioning; (b) Choline ® CDP-PC flux; (c) 
Choline-derived methionine ® PEMT-PC flux; (d) Betaine ® DMG flux. 
In line with this finding, genotype interacted with reproductive state and choline intake to 
influence the flux of choline ® CDP-PC (p = 0.05) and choline-derived methionine ® PEMT-
PC (p = 0.05) (Table S1). The only detectable differences were among lactating women in the 
lower choline intake group. Within this subset, variants exhibited a lower turnover of both 
choline ® CDP-PC (2345 ± 264 vs. 3538 ± 364 µM PC/study period; p = 0.06) and choline-derived 
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methionine ® PEMT-PC (7182 ± 799 vs. 12358 ± 1130 µM PC/study period; p = 0.003) as 
compared to non-variants (Table 7, Figure 4b,c). 
Table 7. CHDH rs12676 genotype alters the metabolic flux of plasma choline 
metabolites.  
Metabolic Outcome 
480 mg  
Choline/day  
WT 
480 mg  
Choline/day  
Variant 
p-
Value 
930 mg  
Choline/day  
WT 
930 mg  
Choline/day  
Variant 
p-
Value 
Choline ® CDP-
PC  
3-Way Interaction; 
p = 0.05 
      
Lactating 3538 ± 364 2345 ± 264 0.06 2779 ± 246 2394 ± 350 >0.99 
Non-pregnant 3127 ± 266 2782 ± 403 >0.99 2621 ± 312 2764 ± 285 >0.99 
Pregnant 4080 ± 285 4809 ± 263 0.39 4021 ± 248 3609 ± 313 >0.99 
Choline-Derived 
Methionine ® 
PEMT-PC 3-Way 
Interaction; p = 
0.05 
      
Lactating 12358 ± 1130 7182 ± 799 0.003  9151 ± 799 8467 ± 1304 >0.99 
Non-pregnant 9334 ± 854 10451 ± 1304 >0.99 9338 ± 1010 9272 ± 922 >0.99 
Pregnant 9668 ± 922 10782 ± 854 >0.99 8728 ± 799 7929 ± 1010 >0.99 
Notes: Values are least-squared means ± standard errors. Choline ® CDP-PC and choline-
derived methionine ® PEMT-PC values are in µM PEMT-PC/study period. p-values 
represent the highest order interaction or main effect and pairwise comparisons between 
genotypes within intake groups. 
Abbreviations: CDP, cytidine diphosphate; CHDH, choline dehydrogenase; PC, 
phosphatidylcholine; PEMT, Phosphatidylethanolamine N-methyltransferase; WT, wildtype. 
Finally, genotype tended to interact with reproductive state to influence the metabolic flux 
of betaine ® DMG (p = 0.09). Non-pregnant variant women exhibited greater turnover of 
betaine ® DMG as compared to non-pregnant non-variant women (6.9 ± 1.3 vs. 6.5 ± 1.3 µM 
DMG/study period; p = 0.01) (Table 8, Figure 4d). 
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Table 8. Comparison of betaine ® DMG turnover between CHDH rs12676 genotype 
by reproductive state.  
Metabolic Outcome and Group  WT Variant p-Value 
Betaine ® DMG  
RS × Gene Interaction; p = 0.09 
   
Lactating 6.5 ± 1.3 6.9 ± 1.3 >0.99 
Non-pregnant 6.4 ± 1.3 12.7 ± 1.5 0.01 
Pregnant 4.5 ± 1.2 5.5 ± 1.3 >0.99 
Notes: Values are least-squared means ± standard errors in µM DMG /study 
period. p-values represent the highest order interaction or main effect and 
pairwise comparisons between genotypes. 
Abbreviations: CHDH, choline dehydrogenase; PC, phosphatidylcholine; 
WT, wildtype. 
D. BHMT rs3733890 
Genotype influenced the metabolic flux of choline ® betaine (p = 0.03) and choline ® CDP-
PC (p = 0.03) and accordingly, the partitioning of dietary choline between betaine and CDP-
PC (p = 0.07) (Table S1, Figure 5). Variant women exhibited a greater turnover of choline ® 
CDP-PC (3440 ± 122 vs. 3063 ± 122 µM PC/study period; p = 0.03) and a non-significantly lower 
turnover of choline ® betaine (32 ± 3 vs. 38 ± 3 µM betaine/study period; p = 0.2) (Although the 
model effect of genotype was significant for the metabolic flux of choline ® betaine, the 
comparison between the two genotypes was not, the difference being that the model effect does 
not account for the presence of a reproductive state by choline intake interaction.) (Table 9, 
Figure 5a,b). Consistent with these findings, variant individuals tended to have lower betaine-
d9/PC-d9 enrichment ratios as compared to non-variants (0.77 ± 0.02 vs. 0.82 ± 0.02; p = 0.07) 
(Table 9, Figure 5c). 
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(a) (b) 
 
(c) 
Figure 5. Effect of the BHMT rs3733890 variant on the metabolic flux and partitioning 
of dietary choline. (a) Choline ® betaine flux; (b) Choline ® CDP-PC flux; (c) 
Betaine-d9/PC-d9 partitioning. 
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Table 9. BHMT rs3733890 genotype alters plasma choline metabolite partitioning and 
flux.  
Metabolic Outcome WT Variant p-Value 
Choline ® Betaine 38 ± 3 32 ± 3 0.2 
Choline ® CDP-PC 3063 ± 122 3440 ± 122 0.03 
Betaine-d9/PC-d9 0.82 ± 0.02 0.77 ± 0.02 0.07 
Notes: Values are least-squared means ± standard errors for each group. 
Betaine-d9/PC-d9 values are ratios, choline ® betaine values are in µM 
betaine/study period and choline ® CDP-PC values are in µM PC/study 
period. 
Abbreviations: BHMT, betaine homocysteine methyltransferase; CDP, 
cytidine diphosphate; PC, phosphatidylcholine; WT, wildtype. 
E. PEMT rs4646343 
Genotype influenced partitioning of dietary choline between PEMT-PC and CDP-PC 
(Table S1, Figure 6). Women with the variant allele exhibited lower PC-d3+6/PC-d9 enrichment 
ratios as compared to women without (0.30 ± 0.008 vs. 0.32 ± 0.009; p = 0.05) (Table 10, Figure 
6a). 
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(c) 
Figure 6. Effect of the PEMT rs4646343 variant on the metabolic flux and partitioning 
of dietary choline. (a) PC-d3+6/PC-d9 partitioning; (b) Betaine ® methionine flux; (c) 
Choline-derived methionine ® PEMT-PC flux. 
Table 10. PEMT rs4646343 genotype alters plasma choline PC-d3+6/PC-d9 
enrichment ratios. Values are least-squared means ± standard errors for each group. 
Values are ratios. 
Metabolic Outcome WT Variant p-Value 
PC-d3+6/PC-d9 0.32 ± 0.009 0.30 ± 0.008 0.05 
Notes: Values are least-squared means ± standard errors for each group in 
ratios. 
Abbreviations: PC, phosphatidylcholine; PEMT, 
Phosphatidylethanolamine N-methyltransferase; WT, wildtype. 
Genotype also interacted with reproductive state to influence the metabolic flux of 
betaine ® methionine (p = 0.08), though individual effects of genotype were not detectable 
after stratifying by reproductive state. Finally, genotype interacted with choline intake and 
reproductive state to influence the metabolic flux of choline-derived methionine ® PEMT-
PC (p = 0.04), though individual effects of genotype were not detectable after stratifying 
by choline intake (Figure 6b,c). 
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F. PEMT rs7946 
Genotype interacted with reproductive state to influence the partitioning of dietary choline 
between PEMT-PC and CDP-PC (p = 0.097) (Table S1, Figure 7a). While genotypic 
differences in PC-d3+6/PC-d9 enrichment ratios were not observed among pregnant and non-
pregnant women, lactating variant women exhibited lower PC-d3+6/PC-d9 enrichment ratios as 
compared to lactating non-variant women (0.29 ± 0.01 vs. 0.37 ± 0.03; p = 0.03) (Table 11). 
 
(a) (b) 
Figure 7. Effect of the PEMT rs7946 variant on the metabolic flux and partitioning of 
dietary choline. (a) PC-d3+6/PC-d9 partitioning; (b) Choline-derived methionine ® 
PEMT-PC flux. 
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Table 11. Comparison of PC-d3+6/PC-d9 enrichment ratios between PEMT rs7946 
genotype by reproductive state. 
Metabolic Outcome and Group WT Variant p-Value 
PC-d3+6/PC-d9  
RS × Gene Interaction; p = 0.09 
   
Lactating 0.37 ± 0.03 0.29 ± 0.01 0.03 
Non-pregnant 0.32 ± 0.02 0.33 ± 0.01 >0.99 
Pregnant 0.30 ± 0.04 0.29 ± 0.01 >0.99 
Notes: Values are least-squared means ± standard errors for each group in ratios. 
Abbreviations: PC, phosphatidylcholine; PEMT, Phosphatidylethanolamine N-
methyltransferase; WT, wildtype. 
In addition, genotype influenced the metabolic flux of choline-derived methionine ® 
PEMT-PC (Table S1, Figure 7b). Variant women had non-significantly greater turnover of 
choline-derived methionine ® PEMT-PC as compared to non-variants (9481 ± 312 vs. 7942 ± 765 
µM PC/study period; p = 0.07) (Table 12). 
Table 12. PEMT rs7946 genotype alters the metabolic flux of choline-derived methionine ® 
PEMT-PC in plasma.  
Metabolic Outcome WT Variant p-Value 
Choline-Derived Methionine ® PEMT-PC 7942 ± 765 9481 ± 312 0.07 
Notes: Values are least-squared means ± standard errors for each group in µM 
PC/study period. 
Abbreviations: PC, phosphatidylcholine; PEMT, Phosphatidylethanolamine N-
methyltransferase; WT, wildtype. 
G. FMO3 rs2266782 
Variant women had greater turnover of betaine ® methionine (1.6 ± 0.05 vs. 1.8 ± 0.05 µM 
methionine/study period; p = 0.03) and a greater turnover of choline-derived methionine ® 
PEMT-PC (9761 ± 384 vs. 8609 ± 433 µM PC/study period; p = 0.05) as compared to non-variants 
(Table 13, Figure 8). 
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Table 13. FMO3 rs2266782 genotype alters the metabolic flux of plasma choline 
metabolites.  
Metabolic Outcome WT Variant p-Value 
Betaine ® Methionine 1.8 ± 0.05 1.6 ± 0.05 0.03 
Choline-Derived Methionine ® PEMT-PC 8609 ± 433 9761 ± 384 0.05 
Notes: Values are least-squared means ± standard errors for each group. Betaine ® 
methionine values are in µM methionine/study period and choline-derived methionine 
® PEMT-PC values are in µM PC/study period. 
Abbreviations: FMO3, Flavin monooxygenase isoform 3; PC, phosphatidylcholine; 
PEMT, Phosphatidylethanolamine N-methyltransferase; WT, wildtype. 
 
(a) (b) 
Figure 8. Effect of the FMO3 rs3733890 variant on the metabolic flux and partitioning 
of dietary choline. (a) Betaine ® methionine flux; (b) Choline-derived methionine ® 
PEMT-PC flux. 
H. SLC44A1 rs7873937 
Genotype interacted with choline intake to influence the turnover of betaine ® methionine (p 
= 0.06) (Table S1, Figure 9a). Although non-variants did not exhibit differences in the turnover 
of betaine ® methionine as a function of choline intake, variant women exhibited greater 
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betaine ® methionine turnover in the higher choline intake group as compared to the lower 
intake group (1.95 ± 0.11 vs. 1.51 ± 0.12 µM methionine/study period; p = 0.03) (Table 14). 
 
(a) (b) 
 
(c) (d) 
Figure 9. Effect of the SLC44A1 rs7873937 variant on the metabolic flux and 
partitioning of dietary choline. (a) Betaine ® methionine flux; (b) Betaine ® DMG 
flux; (c) Choline-derived methionine ® PEMT-PC flux; (d) PC-d3+6/PC-d9 
partitioning. 
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Table 14. Comparison of choline ® CDP-PC turnover between SLC44A1 rs7873987 
genotypes by choline intake group.  
Metabolic Outcome and Group 480 mg Choline/day 930 mg Choline/day p-Value 
Betaine ® Methionine  
Cho × Gene Interaction;  
p = 0.06 
   
WT 1.60 ± 0.06 1.70 ± 0.06 0.9 
Variant 1.51 ± 0.12 1.95 ± 0.11 0.03 
Notes: Values are least-squared means ± standard errors in µM methionine/study 
period. 
Abbreviations: SLC44A1, solute carrier 44A1; WT, wildtype. 
In addition, genotype interacted with reproductive state and choline intake to influence the 
metabolic flux of betaine ® DMG (p = 0.04) (Table S1, Figure 9b). While genotypic 
differences were not observed in the lower choline intake group, within the higher intake group, 
non-pregnant variant women exhibited a greater turnover of betaine ® DMG (19.6 ± 3.3 vs. 7.5 
± 1.5 µM DMG/study period; p = 0.02) (Table 15). Furthermore, similar to betaine ® methionine 
turnover, although non-variants did not display differences in betaine ® DMG as a function of 
choline intake (p > 0.99), variant non-pregnant women exhibited increased betaine ® DMG in 
the higher choline intake group as compared to the lower intake group (19.6 ± 3.3 vs. 5.6 ± 3.3 µM 
DMG/study period; p = 0.05) (Table 16). 
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Table 15. SLC44A1 rs7873987 genotype alters the metabolic flux of betaine ® DMG.  
Metabolic 
Outcome  
and Group 
480 mg  
Choline/day  
WT 
480 mg  
Choline/day  
Variant 
p-
Value 
930 mg  
Choline/day  
WT 
930 mg  
Choline/day  
Variant 
p-
Value 
Betaine ® 
DMG  
3-Way 
Interaction;  
p = 0.04  
      
Lactating 6.2 ± 1.5 6.7 ± 3.3 >0.99 7.4 ± 1.5 5.7 ± 3.3 >0.99 
Non-pregnant 9.2 ± 1.6 5.6 ± 3.3 >0.99 7.5 ± 1.5 19.6 ± 3.3 0.02 
Pregnant 3.8 ± 1.5 4.5 ± 2.3 >0.99 5.6 ± 1.4 7.1 ± 3.3 >0.99 
Notes: Values are least-squared means ± standard errors in µM DMG/study period. p-values 
represent the highest order interaction and pairwise comparisons between genotypes within 
intake groups. 
Abbreviations: DMG, dimethylglycine; SLC44A1, solute carrier 44A1; WT, wildtype. 
Genotype also interacted with reproductive state and choline intake to influence the 
metabolic flux of choline-derived methionine ® PEMT-PC (p = 0.05) (Table S1 and Figure 
9c). Genotypic differences were not detected within intake groups, however, variant and non-
variant women responded differently to increased choline intake in a manner that depended 
upon reproductive state (Table 16). Specifically, only pregnant women with the variant 
exhibited different metabolic flux of choline-derived methionine ® PEMT-PC between intake 
groups with lower flux in the higher intake group as compared to the lower intake group (5780 
± 1658 vs. 11635 ± 1172 µM PEMT-PC/study period; p = 0.07). 
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Table 16. SLC44A1 rs7873987 genotype alters the metabolic flux and partitioning of 
dietary choline.  
Metabolic 
Outcome 
and Group 
480 mg  
Choline/day  
WT 
930 mg  
Choline/day  
WT 
p-
Value 
480 mg  
Choline/day  
Variant 
930 mg  
Choline/day  
Variant 
p-
Value 
Betaine ® 
DMG  
3-Way 
Interaction; p 
= 0.04 
      
Lactating 6.2 ± 1.5 7.4 ± 1.5 >0.99 6.7 ± 3.3 5.7 ± 3.3 >0.99 
Non-pregnant 9.2 ± 1.6 7.5 ± 1.5 >0.99 5.6 ± 3.3 19.6 ± 3.3 0.05 
Pregnant 3.8 ± 1.5 5.6 ± 1.4 >0.99 4.5 ± 2.3 7.1 ± 3.3 >0.99 
Choline-
Derived 
Methionine 
®  
PEMT-PC  
3-Way 
Interaction; 
p = 0.05 
      
Lactating 8759 ± 741 8197 ± 782 >0.99 9648 ± 1658 12417 ± 1658 >0.99 
Non-pregnant 9772 ± 829 9331 ± 782 >0.99 9257 ± 1658 9172 ± 1658 >0.99 
Pregnant 9660 ± 782 8900 ± 707 >0.99 11635 ± 1172 5780 ± 1658 0.07 
PC-d3+6/ 
PC-d9  
3-Way 
Interaction;  
p = 0.08 
      
Lactating 0.27 ± 0.02 0.34 ± 0.02 0.05 0.21 ± 0.04 0.39 ± 0.04 0.02 
Non-pregnant 0.28 ± 0.02 0.37 ± 0.02 0.005 0.31 ± 0.04 0.35 ± 0.04 >0.99 
Pregnant 0.25 ± 0.02 0.33 ± 0.02 0.006 0.26 ± 0.03 0.29 ± 0.04 >0.99 
Notes: Values are least-squared means ± standard errors. Betaine ® DMG values are in µM 
DMG/study period. p-values represent the highest order interaction and pairwise comparisons 
between genotypes within intake groups. 
Abbreviations: DMG, dimethylglycine, SLC44A1, solute carrier 44A1;  PC, 
phosphatidylcholine; PEMT, Phosphatidylethanolamine N-methyltransferase; WT, wildtype. 
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Finally, genotype interacted with reproductive state and choline intake to influence the 
partitioning of dietary choline between PEMT-PC and CDP-PC (p = 0.08) (Figure 9d). 
Genotypic differences were not detected within intake groups; however, variant and non-variant 
women responded differently to increased choline intake in a manner that depended upon 
reproductive state (Table 16). Specifically, across reproductive states, women without the 
variant exhibited greater PC-d3+6/PC-d9 enrichment ratios in the higher choline intake group as 
compared to the lower (p ≤ 0.05). Among women with the variant however, only lactating 
women exhibited increased PC-d3+6/PC-d9 enrichment ratios in the higher choline intake group 
as compared to the lower (p = 0.02) (Table 16). 
I. SLC44A1 rs3199966 
Genotype interacted with choline intake to influence the turnover of betaine ® methionine 
(p = 0.08). While non-variants did not exhibit differences in the turnover of betaine ® 
methionine as a function of choline intake, variant women exhibited greater betaine ® 
methionine turnover in the higher choline intake group as compared to the lower intake group 
(1.90 ± 0.11 vs. 1.52 ± 0.096 µM methionine/study period; p = 0.04) (Table 17, Figure 10). 
Table 17. Comparison of betaine ® methionine turnover between SLC44A1 rs3199966 
genotypes by choline intake group.  
Metabolic Outcome and Group 480 mg Choline/day 930 mg Choline/day p-Value 
Betaine ® Methionine  
Cho × Gene Interaction; p = 0.08 
   
WT 1.60 ± 0.06 1.70 ± 0.06 >0.99 
Variant 1.52 ± 0.10 1.90 ± 0.11 0.04 
Notes: Values are least-squared means ± standard errors in µM methionine/study period. p-
values represent the highest order interaction and pairwise comparisons between intake 
groups within genotypes. 
Abbreviations: SLC44A1, solute carrier 44A1; WT, wildtype. 
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Figure 10. Effect of the SLC44A1 rs3199966 variant on the metabolic flux and 
partitioning of dietary choline. 
  
SLC44A1 rs3199966
Reproductive State
Choline Intake x Genotype interaction; p = 0.08 
Be
ta
in
e 
 →
 M
et
hi
on
in
e 
Fl
ux
 (µ
M
 M
et
hio
nin
e 
/ S
tu
dy
 P
er
iod
)
Lactating NP Pregnant Lactating NP Pregnant
TG & GGTT
930 mg choline/day 480 mg choline/day 
 85 
 
Discussion 
These results demonstrate that common genetic variants in choline metabolizing genes alter the 
metabolic signature of choline in three ways: (i) the use of dietary choline as a methyl donor 
(CHKA rs10791957, CHDH rs9001, CHDH rs12676, PEMT rs4646343, PEMT rs7946, FMO3 
rs2266782, SLC44A1 rs7873937 and SLC44A1 rs3199966); (ii) the partitioning of dietary 
choline between betaine and CDP-PC synthesis (CHDH rs9001 and BHMT rs3733890); and 
(iii) the distribution of dietary choline between PEMT-PC and CDP-PC (CHKA rs10791957, 
CHDH rs12676, PEMT rs4646343, PEMT rs7946 and SLC44A1 rs7873937). Such metabolic 
differences may contribute to disease pathogenesis and prognosis over the long-term. 
A. CHKA (dbSNP: rs10791957; NC_000011.10: g.68100081 C > A) 
Choline kinase-α catalyzes the cytosolic phosphorylation of choline to phosphocholine, which 
comprises the first step of the CDP-PC pathway. The rs10791957 SNP is located in the first 
intron, a possible enhancer region, and is associated with a decreased risk of organ dysfunction 
in women deprived of choline, as well as a decreased risk of type 2 diabetes [10,11]. Although 
the rate-limiting step in the CDP-PC pathway is considered to be the nucleotidyl transfer of 
CDP to phosphocholine, catalyzed by phosphocholine cytidylytransferase, differences in 
CHKA expression influence cellular PC production [23]. CHKA expression contributes to the 
regulation of cellular proliferation and apoptosis and CHKA overexpression and 
phosphocholine accumulation are associated with increased proliferation and oncogenesis 
[24,25]. Furthermore, tissue-specific CHKA expression (modulated in part by the circadian 
clock), has been proposed as a possible regulatory mechanism for the CDP-PC pathway [26]. 
Our data support a role for the CHKA rs10791957 variant as an additional factor that may 
modulate PC homeostasis. Specifically, the variant appears to decrease the use of dietary 
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choline for PEMT-PC synthesis relative to CDP-PC synthesis. Variant individuals displayed 
decreased turnover of choline-derived methionine ® PEMT-PC over the study period, 
indicating decreased activity of PEMT relative to women without the variant, and also tended 
to exhibit lower relative PEMT-PC/CDP-PC enrichment as compared to non-variants. These 
differences may be direct (arising from altered CHKA activity) or indirect (arising from 
changes in downstream signaling that regulate phospholipid metabolism) consequences of 
differences in CHKA expression. Notably, the decreased PEMT activity observed among 
variant women may provide a metabolic basis for the decreased risk of type 2 diabetes among 
variant individuals given that PEMT knockout mice are protected from high-fat diet induced 
obesity and insulin resistance (though not protected from hepatic steatosis) [27]. Additional 
studies are needed to determine whether CHKA rs10791957 genotype distribution influences 
the relationship between diet, obesity and insulin resistance. 
B. CHDH (dbSNP: rs9001; c.119 A > C; p.Glu40Ala) and (dbSNP: rs12676; c.233T > G; 
p.Leu78Arg) 
CHDH is a flavin-dependent, mitochondrial enzyme that oxidizes choline to betaine 
aldehyde. The CHDH rs9001 variant is associated with a decreased risk of choline deficiency, 
while the rs12676 variant is associated with an increased risk among pre-menopausal women, 
which suggests opposing effects of these variants on CHDH activity [28]. 
Our results suggest that women with the rs9001 variant partition dietary choline to the 
CDP-choline pathway at the expense of betaine synthesis. Specifically, rs9001 variant lactating 
women exhibited increased turnover of choline ® CDP-PC as well as non-significantly 
decreased betaine-d9/PC-d9 enrichment ratios in the lower intake group (Figure 3). They also 
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exhibited slightly and non-significantly lower PC-d3+6/PC-d9 enrichment ratios (0.29 ± 0.01 vs. 
0.31 ± 0.01; p = 0.1), further supporting the notion that women (particularly lactating women) 
with the rs9001 variant may relatively favor CDP-PC synthesis over PEMT-PC synthesis. This 
relatively greater use of choline for CDP-PC synthesis as compared to PEMT synthesis among 
CHDH rs9001 variants may conserve choline stores. For example, while each unit of choline 
directed to the CDP-choline pathway yields one unit of PC, choline converted to betaine (and 
eventually SAM) has many metabolic fates besides PEMT-PC production and requires three 
choline-derived methyl groups to yield just one additional unit of PC. In direct contrast, CHDH 
rs12676 variant women appear to favor the use of dietary choline for PEMT-PC synthesis 
relative to CDP-PC. rs12676 variant women exhibited higher PC-d3+6/PC-d9 enrichment ratios, 
non-pregnant rs12676 variant women exhibited a greater use of choline as a methyl donor, and 
lactating rs12676 variant women exhibited greater use of choline for PEMT-PC synthesis and 
lower use of choline for CDP-PC synthesis within the study period as compared to non-variants 
(Figure 4). 
Importantly, our findings identify opposite metabolic differences for these variants, which 
is consistent with a decreased and increased risk of choline deficiency, respectively as 
previously reported by others [10,14]. In some ways, however, our data appear to contrast 
previous work, possibly due to a different effect of these variants by tissue, sex (the CHDH 
gene is under the control of an estrogen promoter), diet and other environmental factors [29]. 
Specifically, the rs12676 variant confers a relative loss of function in male sperm as variant 
men exhibit decreased sperm ATP and dyspmorphic mitochondrial structures similar to Chdh−/− 
mice, as well as decreased CHDH protein in sperm [14]. The mechanism however is unclear 
and it is unknown whether this effect is due to increased expression of CHDH or decreased 
 88 
 
degradation. Additionally, a previous study identified increased dimethyl-arsenic:mono-methyl 
arsenic in CHDH rs9001 variant individuals exposed to arsenic, indicating increased efficiency 
of arsenic methylation [12]. The authors postulated that this increased efficiency of arsenic 
methylation (which facilitates detoxification) among rs9001 variant individuals may be due to 
a gain of function in CHDH activity that increases the conversion of choline to betaine, 
increasing SAM availability. Another possible interpretation is that the variant comprises a loss 
of CHDH activity. Decreased conversion of choline to betaine might increase the availability 
of choline for CDP-PC synthesis, reducing the burden on SAM for PC synthesis (PEMT is one 
of the main consumers of SAM in the liver), and increasing the availability of SAM for arsenic 
methylation. Overall, our results highlight that the CHDH rs9001 and CHDH rs12676 SNPs 
exert opposing metabolic effects, not only among individuals deprived of choline or exposed to 
one-carbon stressing conditions, but also among healthy women consuming choline intakes 
relevant to the general population. 
C. BHMT (dbSNP: rs3733890; c.716 G > A, also known as c.742 G > A; p.Arg239Gln) 
Betaine homocysteine methyltransferases (BHMT) is a zinc-dependent enzyme that uses 
betaine to remethylate homocysteine to methionine. It acts primarily in the liver, but is also 
present in the kidney and optic lens. The BHMT rs3733890 variant encodes an arginine to 
glutamine change at amino acid 239, which results in a lower Km (roughly half) for both betaine 
and homocysteine [30]. The BHMT rs3733890 polymorphism has been associated with reduced 
all-cause mortality in breast cancer patients and a number of developmental outcomes including 
a decreased risk of orofacial cleft and an increased risk of spina bifida, particularly with high 
maternal folic acid intake, but results have been mixed [15–18,31]. There is some evidence that 
the effect of this variant is modulated by MTHFR rs1801133 variant allele presence, however 
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the relationship remains unresolved [18]. Given the scarcity of MTHFR rs1801133 and BHMT 
rs3733890 homozygous variant individuals in our cohort, this study was unable to examine this 
interaction. When evaluated independently, the BHMT variant allele was associated with non-
significantly decreased turnover of choline ® betaine, and increased turnover of choline ® 
CDP-PC as well as a (non-significantly, p = 0.07) lower betaine-d9/PC-d9 enrichment ratio. 
Together, these results indicate that the variant favors the use of dietary choline for CDP-PC 
synthesis at the expense of betaine synthesis. These findings can be understood in the context 
of the effect of this SNP on enzyme kinetics. A lower Km for both betaine and homocysteine, 
results in increased affinity of the enzyme for these substrates, meaning less betaine is needed 
among variants to maintain maximal BHMT activity. Partitioning away from betaine, therefore, 
may conserve dietary choline among variant individuals. 
D. PEMT (dbSNP: rs4646343; c.2768 C > A REV) and (dbSNP: rs7946; c.5465 G > A REV; 
p.Val175Met) 
Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the de novo synthesis of 
choline via the triple methylation of PE to form PC [32]. The PEMT rs7946 variant encodes a 
valine to methionine substitution at amino acid 175, which results in decreased enzymatic 
activity in vitro and may increase susceptibility to non-alcoholic fatty liver disease (NAFLD) 
[20,21]. Previous work has found a 92% overlap of the intronic PEMT rs4646343 SNP with the 
functional rs12325817 SNP, which is located in the promoter region of the PEMT gene, near 
the estrogen response element, and impedes its estrogen-mediated up-regulation [33]. This 
impairment leads to an increased susceptibility to organ dysfunction in variant individuals [10]. 
Although we did not observe direct indications of decreased PEMT activity, the observed 
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decreased PEMT-PC/CDP-PC in rs4646343 variant individuals is consistent with decreased 
PEMT activity and an impaired estrogen response among variant individuals. Decreased 
PEMT-PC/CDP-PC was also observed in PEMT rs7946 variant lactating women. 
Overall, these data suggest a relatively decreased contribution of PEMT-PC relative to 
CDP-PC in PC pools with both PEMT rs4646343 and rs7946 variants. Impaired PEMT activity 
may compromise PC-DHA supply to extra-hepatic tissue including vital reproductive organs 
during pregnancy and lactation [34]. Therefore, given that these data support the notion that 
both PEMT variants lead to functional changes in PC homeostasis at choline intakes meeting 
current recommendations, these SNPs deserve further study to determine whether such effects 
are associated with negative clinical outcomes among the general population, whose intakes are 
well below current recommendations [35]. 
E. FMO3 (dbSNP: rs2266782; c.472 G > A; p.Glu158Lys) 
FMO3 is a (largely) hepatic enzyme that converts trimethylamine, a breakdown product of 
choline produced by anaerobic intestinal microbiota, to trimethylamine N-oxide (TMAO) [36]. 
The rs2266782 SNP is a common polymorphism that encodes a glutamate to lysine amino acid 
change (E158K) in flavin monooxygenase isoform 3 (FMO3) [37]. This variant is associated 
with a relative loss-of-function and, when in cis with other common variants, can cause mild 
trimethylaminuria (due to a relative excess of trimethylamine), which has largely unknown 
metabolic consequences [22]. FMO3 is activated by insulin, and knockout in insulin resistant 
mice prevents hyperglycemia, hyperlipidemia, and atherosclerosis [38]. FMO3 is suppressed 
by testosterone and up regulated by bile acids, which also stimulate hepatic cholesterol 
absorption [39]. 
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Differences in TMAO metabolism are known to alter cholesterol transport and influence 
risk for cardiovascular disease [40,41]. TMAO supplementation in mice has been shown to 
increase macrophage cholesterol accumulation, which subsequently increases risk for 
atherosclerosis [41]. More recently, Brown and colleagues identified FMO3 itself (rather than 
TMAO) as a direct regulator of cholesterol balance, lipid metabolism, and inflammation in 
mice. FMO3 knockdowns had decreased hepatic cholesterol production, decreased intestinal 
absorption, and increased hepatic inflammation along with activation of liver X receptor 
(LXR)-stimulated macrophage reverse cholesterol transport [42]. While a previous study from 
our group suggested that the variant might be associated with increased use of choline as a 
methyl donor in men (based on increased DMG pool size) [43], results from the present study, 
indicate that women with the variant actually use choline less as methyl donor. Variant women 
tended to have a lower turnover of betaine ® methionine over the study period. In addition, 
variant women exhibited a greater turnover of choline-derived methionine ® PEMT-PC over 
the study period, which is consistent with previous findings from our lab that have identified 
lower methionine excretion among variant individuals (i.e., a greater use of methionine may 
reduce excretion) [43]. While it is not clear how these findings relate to data in mice, our results 
strengthen previous evidence of a relationship between FMO3 and phospholipid metabolism 
and demonstrate that this SNP exerts an effect on the metabolic use of dietary choline. 
F. SLC44A1 (dbSNP: rs7873937; NC_000009.11:g.108089321 G > C) and SLC44A1 
(dbSNP: rs3199966; c.1930 T > G; p.Ser644Ala) 
Solute Carrier 44A1 (SLC44A1), also referred to as choline transporter-like protein 1 
(CTL1), is a transmembrane protein that mediates choline transport across the mitochondrial 
 92 
 
and plasma membranes [44–46]. It is expressed in four major splice variants throughout the 
brain and central nervous system including the spinal cord, motor neurons, and 
oligodendrocytes during and after myelination, as well as in the colon and lung. While the 
majority of people present with liver dysfunction in response to choline deprivation, Zeisel and 
colleagues noted that some individuals present first with muscle dysfunction, and they tend to 
carry mutations in the SLC44A1 gene [10]. Though not exonic, the SLC44A1 rs7873937 variant 
allele is associated with an increased susceptibility to muscle dysfunction in humans deprived 
of choline [10]. SLC44A1 rs7873937 may exist in a regulatory region that responds to choline 
status, or may be in linkage disequilibrium with a functional SNP. The rs3199966 
polymorphism confers a serine to alanine amino acid substitution, and like rs7873937, is 
associated with increased susceptibility to muscle dysfunction in humans deprived of choline 
[10]. For each of these SNPs, rs7873937 and rs3199966, we identified an interaction between 
genotype and choline intake that governed the use of choline as a methyl donor. The finding 
that the effect of genotype depends on choline intake aligns with in vitro evidence that dietary 
choline is known to modulate expression of the SLC44A1 gene [47]. Specifically, for both 
SNPs, variant (but not non-variant) individuals exhibited greater turnover of betaine ® 
methionine in the higher choline intake group as compared to the lower, suggesting that 
additional choline was used for methyl donation. For SLC44A1 rs7873937, this effect was 
partially mirrored in a greater turnover of betaine ® DMG at the higher choline intake among 
non-pregnant women. While we expect that betaine ® DMG and betaine ® methionine 
turnover would be identical, our results are not exactly the same, and this is likely due to 
differences in choline partitioning and sequestration throughout the various pools in the body. 
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G. Study Limitations 
Given the post-hoc design, which did not preemptively evenly distribute participants across 
reproductive states, choline intake groups, and genotypes, some comparisons that involved two- 
and three-way interactions ended up with small sample sizes. Other limitations include possible 
unequal distribution of other functional variants within the study population, and the fact that 
circulating metabolites may not be in equilibrium with all tissues. Nonetheless, the present 
study benefitted from a highly controlled study environment and the precision afforded from 
the use of an isotopic tracer. 
Conclusion 
These data provide compelling evidence that common SNPs modulate choline partitioning in 
women of reproductive age consuming intakes that are relevant to the population at large. These 
metabolic differences may contribute to disease pathogenesis and prognosis over the long-term 
given relationships between methyl group and PC homeostasis and disease. Therefore, these 
SNPs deserve further study in a clinical and epidemiological context. 
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Supplemental Information 
Table S1. Effect of SNP genotype and interaction (p-values) on plasma choline 
metabolite partitioning and flux. 
Outcome Gene G*RS G*Cho Three-Way 
CHKA rs10791957     
Betaine-d9/PC-d9 0.6 - - - 
PC-d3+6/PC-d9 0.09 - - - 
Choline → Betaine 0.8 - - - 
Choline → CDP-PC 0.3 - - - 
Betaine → DMG 0.5 - - - 
Betaine → Methionine 0.6 - - - 
Methionine → PEMT-PC 0.0005 - - - 
CHDH rs9001     
Betaine-d9/PC-d9 0.2 - 0.07 - 
PC-d3+6/PC-d9 0.1 - - - 
Choline → Betaine 0.6 - - - 
Choline → CDP-PC 0.7 0.04   
Betaine → DMG 0.2 - - - 
Betaine → Methionine 0.9 - - - 
Methionine → PEMT-PC 0.9 - - - 
CHDH rs12676     
Betaine-d9/PC-d9 0.2 - - - 
PC-d3+6/PC-d9 0.055 - - - 
Choline → Betaine 0.3 - - - 
Choline → CDP-PC 0.2 0.08 0.9 0.05 
Betaine → DMG 0.03 0.09 - - 
Betaine → Methionine 0.2 - 0.1 - 
Methionine → PEMT-PC 0.2 0.02 0.8 0.05 
BHMT rs3733890     
Betaine-d9/PC-d9 0.066 - - - 
PC-d3+6/PC-d9 0.3 - - - 
Choline → Betaine 0.03 - - - 
Choline → CDP-PC 0.03 - - - 
Betaine → DMG 0.1 - - - 
Betaine → Methionine 0.95 - - - 
Methionine → PEMT-PC 0.15 - - - 
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CHAPTER 3 
 
Vitamin D Binding Protein rs7041 Genotype Alters Vitamin D Metabolism in Pregnant 
Women*# 
Abstract 
Vitamin D inadequacy is highly prevalent among pregnant and lactating women worldwide. 
Previous research has identified reduced circulating 25(OH)D and DBP in individuals with 
the GC rs7041 (c.1296T>G) T allele in the vitamin D binding protein gene (i.e. GC). We 
aimed to further characterize the effects of GC rs7041 on vitamin D metabolism and to 
examine whether this genotype modulates the metabolic changes that occur during pregnancy 
and lactation. In a controlled feeding study that provided 2 doses of choline, healthy third-
trimester pregnant (n=26), lactating (n=28), and non-pregnant (n=21) women consumed a 
single amount of vitamin D (511 IU/d: 311 IU/d from diet and 200 IU/d as supplemental 
cholecalciferol) and related nutrients for 10-12 weeks. Vitamin D biomarkers were measured 
in blood and placenta, and osteocalcin, a biomarker of bone formation, was measured in 
umbilical cord blood. Participants were genotyped for GC rs7041 (GG n=18, GT n=36, TT 
n=20). We found lower serum 25(OH)D among GT (85% of GG, p = 0.1) and TT (80% of 
GG, p = 0.05) individuals. In addition, while GG pregnant women exhibited greater DBP 
(216%, p<0.0001) than GG non-pregnant women, among GT women, this difference was 
dampened (157%, p = 0.001), and TT pregnant women did not exhibit greater DBP than TT 
                                                
*Ganz#, Park# et al. A common genetic variant in vitamin D binding protein GC rs7041 alters 
metabolism and the metabolic response to pregnancy. (Planned Submission July 2017) 
# Co-first authorship 
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non-pregnant women (p = 0.9).  Furthermore, unlike GG pregnant women (140% of GG non-
pregnant women), TT pregnant women did not exhibit greater placental 
25(OH)D3:24,25(OH)2D3 ratios than TT non-pregnant and exhibited lower osteocalcin in the 
cord blood of their neonates (24% of GT, p=0.02). Collectively these data reveal that the GC 
rs7041 genotype modifies the effects of pregnancy on maternal and placental vitamin D 
metabolism, with possible functional consequences for fetal bone development and infant 
health.  
Introduction 
Mounting evidence suggests that vitamin D inadequacy during pregnancy and lactation is 
associated with adverse maternal, fetal, and infant bone health outcomes, as well as other 
adverse maternal outcomes such as preeclampsia, gestational diabetes, obstructed labor, and 
infectious disease.1,2 There have also been reports of adverse fetal outcomes including 
aberrations in growth and developmental programming, as well as adverse infant health 
outcomes.1,2 Despite increasing awareness of these health risks, vitamin D inadequacy, 
defined as serum 25-hydroxyvitamin D [25(OH)D] levels less than 50 nmol/L by the National 
Academy of Medicine, remains highly prevalent among pregnant and lactating women, with 
estimates ranging from 30-96% in different regions worldwide.3  
Serum 25(OH)D concentrations can be influenced by many factors including UV 
exposure, seasonal variation, dietary vitamin D intake, BMI, age, and race/ethnicity. Genetic 
factors may also affect serum 25(OH)D levels, and several genome-wide studies have 
demonstrated that common genetic variants in vitamin D metabolic components are 
significantly associated with serum 25(OH)D concentrations.4,5 Thus, it is of interest to 
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ascertain whether genetic factors modify alterations in vitamin D metabolism that occur 
during pregnancy and lactation, or contribute to individual differences in vitamin D 
requirements in these reproductive states.  
GC rs7041 c.1296T>G is a single nucleotide polymorphism in the vitamin D binding 
protein (DBP) gene that encodes an aspartate to glutamate amino acid change that alters the 
affinity of DBP for 25(OH)D. The T allele of this genotype has been associated with lower 
serum 25(OH)D in some but not all studies.4,6–9 Although previous studies have identified 
differences in circulating 25(OH)D by rs7041 genotype in non-pregnant individuals, the effect 
of the variant on vitamin D biomarkers including 25(OH)D in pregnancy and lactation has not 
been extensively examined.10 
Taking advantage of a highly controlled long-term feeding study previously conducted 
by our research group,11 the present study sought to evaluate the effects of the GC rs7041 
variant on vitamin D metabolism in pregnant, lactating, and non-pregnant/non-lactating 
women consuming vitamin D intakes approaching the 600 IU RDA.  
Participants and Methods 
A. Participants and Study Design   
As part of a 10-12 week controlled feeding study designed to assess the effect of increased 
choline intake during pregnancy and lactation, healthy third-trimester pregnant women 
(n=26), lactating women 5 weeks post-partum (n=28), and non-pregnant women (n=21) were 
randomized to either 480 mg choline/d or 930 mg choline/d. Throughout the controlled 
feeding period,  all participants consumed identical intakes of vitamin D (511 +/- 48 IU/d: 311 
+/- 48 IU/d from diet and 200 IU/d as supplemental cholecalciferol) and related nutrients (1.6 
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+/- 0.4 g Ca/d and 1.9 +/- 0.3 g P/d). Details on the study protocol and diet can be found in 
our previous publication.11 The study was approved by Institutional Review Boards at Cornell 
University (Ithaca, NY, USA) and Cayuga Medical Center (Ithaca, NY, USA) and registered 
at clinicaltrials.gov as NCT01127022 and NCT0305186711–13 All participants provided 
informed consent. 
B. Sample Collection and Processing 
Fasting blood samples (10 h) were collected at study week 10 into a serum separator tube 
(used for serum vitamin D metabolite quantification) and EDTA-coated tubes. Samples were 
placed on ice immediately, and EDTA tubes were centrifuged (2200 rpm, 15 min, 4°C) to 
separate plasma (used for quantification of vitamin D metabolites) from buffy coat (used for 
genotyping). Samples were stored at -80°C until use. Placentas (n=24) were collected and 
processed within 90 minutes of delivery, as previously described.11  Fetal cord blood samples 
(n = 23) were collected at delivery into EDTA-coated tubes and processed accordingly. Two 
placentas and three cord blood samples were not obtained because two participants gave birth 
at home, and one participant gave birth without notifying the research team.11–13 
C. Genotyping 
The commercially available DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA) was 
used to extract DNA from buffy coat samples. Genotyping of GC rs7041 was performed in 
our facility using Endpoint Genotyping on a LightCycler 480 (Roche, Indianapolis, IN, USA) 
and a commercially available mix (Applied Biosystems TaqMan Genotyping Master Mix and 
Assay Mix; Thermo Fisher Scientific, Waltham, MA, USA). Samples were run in duplicate 
with in-run standards and a negative water control. Cycling conditions were as follows: 95°C 
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for 10 min, followed by 34 cycles of 92°C for 15 s and 62°C for 90 s. 
D. Quantification of Vitamin D Metabolites 
25(OH)D, 3-epi 25(OH)D3, & 24,25(OH)2D 
Serum 25(OH)D (the sum of 25(OH)D2 and 25(OH)D3), serum 3-epi 25(OH)D3, and plasma 
24,25(OH)2D were quantified using an isotope dilution LCMS/MS method with modifications 
based on our instrumentation, as previously described.13–15  This same methodology was used 
for placental vitamin D metabolites. Assay precision and accuracy were assessed using the 
National Institute of Standards and Technology SRM and the Vitamin D External Quality 
Assessment Scheme. 
1,25(OH)2D & DBP 
ELISA kits were used to measure plasma 1,25(OH)2D (Immunodiagnostic Systems, Inc., 
Scottsdale, AZ) and DBP (R&D Systems, Minneapolis, MN). 
Free 25(OH)D 
Free 25(OH)D was estimated using an equation as previously described.13 
25(OH)D3 and 24,25(OH)2D3 
Placental 25(OH)D3 and 24,25(OH)2D3 were extracted from homogenized placental tissues as 
previously described (Park et al., submitted 2017). 1mL of methanol was added to 0.4 g of 
homogenized placental tissues along with 600µL of acetonitrile, 1mL of MTBE, and 25µL of 
internal standard containing 215mol/L d3-25(OH)D3 (IsoSciences) and 1.7mol/L d6- 
24,25(OH)2D3 (Toronto Research Chemicals Inc.) A liquid-liquid extraction was followed by 
a solid-phase extraction on Oasis HLB cartridges (3cc/60mg), and subsequent derivatization 
with 50µL of 0.1mg/mL DMEQ-TAD.16,17  Finally, extracts were resuspended in 110µL of 
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60:40 methanol:water and injected onto a PFP column (PFP Accucore 2.1 x 100, 2.6 mm) 
with matching guard column at 45°C, and separated by our LC-MS/MS, a Surveyer HPLC 
system (pump and autosampler) and a TSQ Quantum Ultra mass spectrometer, operated with 
XCalibur (2.2 SP1.48) software (ThermoElectron Corp).12  
Biochemical marker of bone formation in neonates (cord blood) 
Osteocalcin (OC) was measured in cord plasma obtained at delivery using an ELISA kit 
(R&D Systems, Minneapolis, MN).12 
E. Statistical Analysis 
The effect of GC rs7041 genotype on vitamin D metabolism was assessed using linear 
models. Vitamin D metabolites in blood and placenta were modeled as a function of rs7041 
genotype. Reproductive status, BMI, season, and ethnicity were included as covariates in the 
blood metabolite models, and age was considered as a co-variate and retained in the model at 
an α-cutoff of 0.05. Choline intake level was considered as a covariate but was not significant 
in any model. We used a two-level ethnicity/race outcome, white and non-white (including 
Latino, Black, Asian, and mixed race/other), due to the sparsity of non-white participants, 
though grouping these ethnicities did not change our results.  Interactions between genotype 
and reproductive state were retained at an α-cutoff of 0.1. Analysis with and without 
ethnicity/race in the model yielded the same results. Given that little is known about the 
factors that influence vitamin D outcomes in the placenta and umbilical cord, the change 
method was used to identify co-variates that influenced outcomes and to construct placental 
and umbilical cord blood models. BMI, season, ethnicity (white and non-white), age, infant 
sex, parity, and vitamin supplementation status at baseline were evaluated as possible co-
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variates by examining one at time whether they changed the estimate of genotype by more 
than ten percent as compared to a bivariate model of genotype with the outcome of interest. 
Co-variates that passed this test were assembled into an initial model, and a backwards 
selection was carried out where the co-variate with the highest p-value was eliminated until 
all co-variates included in the model had a p-value less than or equal to 0.2. Standard 
diagnostic methods were used to assess model assumptions and the fit of the models to the 
data. Some models had outliers and not perfectly normal distributions. 24,25(OH)D3 met 
normality criteria after log transformation. ANOVA was determined to be robust enough to 
deal with all other models, and assessment of models that had outliers without their outliers 
yielded normal models with the same results qualitatively in terms of significance. Statistical 
analysis was performed using the lsmeans package in The R Project for Statistical Computing 
environment, available from Comprehensive R Archive Network (CRAN) 2014.18 T-tests 
were used for pairwise comparisons, and reported p-values include adjustments for multiple 
comparisons using the Tukey method and were considered significant at an α-cutoff of 0.05. 
 
Results 
A. Characteristics of the participants 
Baseline characteristics by genotype are displayed in Table 1. 
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Table 1. Baseline Characteristics  
 All n=74 GG n=18 GT n=36 TT n=20 
BMI, kg/m2 24.8+/-5.1 23.3+/-3.4 26.1+/-6.1 23.9+/-3.7 
Ethnicity, n. (%)     
White 49 
(66%) 
13  
(72%) 
23 
(64%) 
13 
(65%) 
Black  4 
(5%) 
1 
(6%) 
1 
(3%) 
2 
(10%) 
Latina  9 
(12%) 
3 
(17%) 
4 
(11%) 
2 
(10%) 
Asian 6 
(8%) 
1 
(6%) 
2 
(6%) 
3 
(15%) 
Other  6 
(8%) 
0 
(0%) 
6 
(17%) 
0 
(0%) 
Season at study entry, n.     
April-September  41 10 19 12 
October-March  33 8 17 8 
Age, y. 28.4+/-5.6 30.3+/-5.2 27.1+/-6.2 29.1+/-4.0 
Non-pregnant Women, n. 21 6 9 6 
Lactating Women, n. 27 3 16 8 
Pregnant Women, n. 26 9 11 6 
Parity, 
primiparas/multiparas 
12/14 5/4 3/8 4/2 
Infant sex, male/female 19/7 6/3 7/4 6/0 
Multivitamin supplement 
use before study entry, n. 
49/74 10/18 26/36 13/20 
Notes: Pregnant women self-reported pre-pregnancy BMIs. Averages are reported +/- 
standard deviations 
Abbreviations: y, year; n, number. 
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B. 25(OH)D 
In line with previous findings, GC rs7041 genotype predicted total 25(OH)D2+3, main effect, p 
= 0.04. The effect of genotype on 25OHD was independent of reproductive state. Individuals 
with one or two copies of the T allele tended to exhibit lower serum 25OHD2+3. The rs7041 
GG genotype had a total 25(OH)D level of 93.5+/- 5.5 nmol/L, vs. heterozygotes, GT, at 79.9+/- 
3.8 nmol/L (p = 0.1) and homozygous TT, at 75.4+/- 5.1 nmol/L (p = 0.04) (Figure 1a, Table 2).    
This effect of genotype on 25(OH)D was most prominent in the D3 component, main 
effect, p = 0.07. Individuals with one or two copies of the T allele tended to exhibit lower 
serum 25(OH)D3. rs7041 GG individuals had a level of 91.8+/-5.5 nmol/L, vs. GT 
heterozygotes at 78.5+/-3.8 nmol/L (p = 0.1) and homozygous TT at 74.2+/-5.1 nmol/L (p = 0.05) 
(Supplemental Figure 1b, Table 2).  Although rs7041 genotype did not significantly predict 
serum 25(OH)D2, p = 0.5, women with the T allele did exhibit non-significantly lower levels 
(Supplemental Figure 1a, Table 2). 
(a)  
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(b)  
 
 
(c) 
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(d) 
 
(e) 
 
Figure 1. Effect of the GC rs7041 genotype on circulating maternal vitamin D metabolites 
at study week 10. Total 25(OH)D was calculated as the sum of 25(OH)D2 and 25(OH)D3. 
Values are least-squared means +/- standard errors. Number of participants in each group: GG 
(n=18), GT (n=36), TT (n=20). Groups that are not labelled with any of the same letters are 
significantly different at an α-cutoff of 0.05. DBP and the 25(OH)D3:24,25(OH)2D3 ratio 
exhibited interactions between GC rs7041 genotype and reproductive state. Number of 
participants in each group for these two outcomes: Lactating (GG n=3, GT n=16, TT n=8); 
Non-Pregnant (GG n=6, GT n=9, TT n=6), Pregnant (GG n=9, GT n=11, TT n=6). 
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Table 2. Circulating vitamin D metabolites among pregnant, lactating, and non-pregnant 
women (combined) at study week 10 
 GG  GT TT 
p-value 
GG vs. GT 
p-value 
GG vs. TT 
p-value 
GT vs. TT 
Total 25(OH)D, nmol/L 
Main effect; p = 0.04 93.5
+/- 5.5 79.9+/- 3.8 75.4+/- 5.1 0.1 0.05 0.8 
25(OH)D2, nmol/L 
Main effect; p = 0.5 1.7
+/-0.4 1.4+/-0.2 1.2+/-0.3 0.8 0.5 0.8 
25(OH)D3, nmol/L 
Main effect; p = 0.05 91.8
+/-5.5 78.5+/-3.8 74.2+/-5.1 0.1 0.05 0.8 
DBP, μg/ml 
Genotype x RS 
interaction; p = 0.0002 
      
Non-Pregnant 313+/-32 237+/-26 125+/-32 0.6 0.003 0.2 
Lactating 415+/-45 172+/-21 79+/-29 0.0004 <0.0001 0.2 
p-value  
vs. Non-Pregnant 0.7 0.6 0.97    
Pregnant 663+/-27 383+/-24 169+/-33 <0.0001 <0.0001 0.0001 
p-value  
vs. Non-Pregnant <0.0001 0.003 0.99    
Free 25(OH)D2,3, 
pmol/L 
Main effect; p = 2x10-9 
18.5+/-3.1 24.3+/-2.1 46.0+/-2.8 0.3 <0.0001 <0.0001 
3-epi-25(OH)D3, 
nmol/L 
Main effect; p = 0.03 
3.8+/-0.5 2.4+/-0.4 1.9+/-0.5 0.09 0.02 0.7 
25(OH)D3: 
24,25(OH)2D3 Ratio 
Genotype x RS 
interaction; p = 0.1 
      
Non-Pregnant 7.0+/-0.7 7.6+/-0.6 6.4+/-0.7 >0.99 >0.99 0.9 
Lactating 9.4+/-1.0 6.9+/-0.5 7.4+/-0.6 0.4 0.7 >0.99 
p-value  
vs. Non-Pregnant 0.5 0.99 0.97    
Pregnant 9.9+/-0.6 7.7+/-0.5 8.4+/-0.7 0.07 0.8 0.99 
p-value  
vs. Non-Pregnant 0.04 >0.99 0.6    
1,25(OH)2D3 208+/-29 228+/-21 204+/-26 0.8 0.99 0.8 
24,25(OH)2D3 10.2+/-1.3 10.1+/-1.0 10.2+/-1.2 0.99 >0.99 0.99 
Notes: Values are least-squared means +/- standard errors. Number of participants in each group: 
GG (n=18), GT (n=36), TT (n=20). Total 25(OH)D was calculated as the sum of 25(OH)D2 and 
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25(OH)D3. No significant interaction was detected between genotype and reproductive state for 
each vitamin D metabolite unless otherwise indicated. Study week 10 DBP and 
25(OH)D3:24,25(OH)2D3 ratios exhibited interactions between GC rs7041 genotype and 
reproductive state and comparisons are also presented within genotypes across reproductive 
states. Number of participants in each group for these two outcomes: Lactating (GG n=3, GT 
n=16, TT n=8); Non-Pregnant (GG n=6, GT n=9, TT n=6), Pregnant (GG n=9, GT n=11, TT 
n=6). 
Abbreviations: DBP, vitamin D binding protein; 3-epi-25(OH)D3, C3 epimer of 25-
hydroxyvitamin D3; Free 25(OH)D, free 25-hydroxyvitamin D; 25(OH)D3, 25-
hydroxyvitamin D3; 24,25(OH)2D3, 24,25-dihydroxyvitamin D3; 1,25(OH)2D3, 1,25-
dihydroxyvitamin D3. 
C. DBP 
The rs7041 polymorphism influenced DBP levels in our cohort in a manner that depended 
upon reproductive state (RS x genotype interaction, p = 0.0002). 
Within each reproductive state, the T allele was associated with lower levels of DBP 
(p<0.003) (Table 2), with the exception of heterozygous non-pregnant women, who were not 
significantly different than GG non-pregnant women. Furthermore, the difference in DBP 
associated with pregnancy varied by rs7041 genotypes. Among the women with the GG 
genotype, GG pregnant women exhibited more than 2x greater DBP than GG non-pregnant 
women (663+/-27µg/mL vs. 313+/-32 µg/mL, p < 0.0001). However, this difference was 
dampened among the GT heterozygotes to roughly 1.6x greater DBP levels in GT pregnant 
women than GT non-pregnant women (383+/-24 µg/mL vs. 237+/-26 µg/mL, p = 0.003). 
Moreover, no difference in DBP was observed between homozygous TT pregnant women and 
non-pregnant TT women (169+/-33 µg/mL vs. 125+/-32 µg/mL, p = 0.99), suggesting that TT 
women do not increase DBP during pregnancy (Figure 1b, Table 2). 
D. Free 25(OH)D 
GC rs7041 genotype was a significant predictor of free circulating 25(OH)D, p = 2 x 10-9. 
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This effect was independent of reproductive state.  Individuals with the TT genotype 
exhibited greater levels (46.0+/-2.8 pmol/L) of free 25(OH)D than those with the GG (18.5+/-3.1 
pmol/L, p < 0.0001) and GT genotypes (24.3+/-2.1 pmol/L, p < 0.0001) (Figure 1c, Table 2). 
E. 3-Epi-25(OH)D3 
In addition, genotype predicted 3-epi-25(OH)D3 (p = 0.03). This effect was independent of 
reproductive state. Additional copies of the T allele were associated with successively lower 
levels of 3-epi-25(OH)D3. Women with the GG genotype exhibited levels of 3.8+/-0.5 nmol/L, 
which were greater than GT (2.4+/-0.4 nmol/L, p = 0.09) and TT (1.9+/-0.5 nmol/L, p = 0.02) 
individuals (Figure 1d, Table 2). 
F. 25(OH)D3:24,25(OH)2D3 ratio 
A genotype by reproductive state interaction tended to predict the 25(OH)D3: 24,25(OH)2D3 
ratio (p = 0.1). Genotypic differences were not observed among non-pregnant and lactating 
women. However, among pregnant women, GG individuals tended to exhibit greater 
25(OH)D3:24,25(OH)2D3 ratios than those with the GT genotype (9.9+/-0.6 vs. 7.7+/-0.5, p = 
0.07) (Figure 1e, Table 2). 
 In addition, the metabolic response to pregnancy appeared to differ between 
genotypes. Among GG individuals, pregnant women tended to exhibit greater 
25(OH)D3:24,25(OH)2D3 ratios than non-pregnant women. GG pregnant women displayed 
25(OH)D3:24,25(OH)2D3 ratios of (9.9+/-0.6, p = 0.04), which were significantly greater, as 
compared to non-pregnant GG women (7.0+/-0.7, p = 0.04).  
 In contrast, pregnant women with the GT and TT genotypes did not exhibit 
significantly greater 25(OH)D3:24,25(OH)2D3 ratios than non-pregnant women with the same 
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genotype. (Figure 1e, Table 2). 
G. 1-25(OH)2D and 24,25(OH)2D3 
Genotypic differences in 1-25(OH)2D and 24,25(OH)2D3 were not detected (Table 2). 
H. Placental 24,25(OH)2D3 
In the placenta, genotype predicted 24,25(OH)2D3 (p = 0.04). Additional copies of the T allele 
were associated with lower levels of 24,25(OH)2D3. Women with the GG genotype exhibited 
levels of 0.88+/-0.27 log(nmol/L), which were greater than GT (0.06+/-0.33 log(nmol/L), p = 0.1) 
and TT (-0.23+/-0.34 log(nmol/L), p = 0.04) individuals (Figure 2a, Table 3). 
(a) 
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(b) 
 
 
(c) 
 
Figure 2. Effect of GC rs7041 genotype on placental vitamin D metabolites. Values are 
least-squared means +/- standard errors. Number of participants in each group: GG (n=8), GT 
(n=10), TT (n=6). Groups that are not labelled with any of the same letters are significantly 
different at an α-cutoff of 0.05 
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I. Placental 25(OH)D3 
Genotypic differences in placental 25(OH)D3 were not detected. However, homozygous TT 
individuals exhibited non-significantly lower placental 25(OH)D3 (Figure 2b, Table 3). 
J. Placental 25(OH)D3/Placental 24,25(OH)2D3 Ratio 
Genotype predicted the 25(OH)D3: 24,25(OH)2D ratio (p = 0.02). Individuals with the 
homozygous TT genotype tended to exhibit greater placental 25(OH)D3:24,25(OH)2D3 ratios 
than those with the GG genotype (22.1+/-4.0 vs. 8.8+/-3.7, p = 0.06) (Figure 2c, Table 3). 
Table 3. Placental vitamin D metabolites and biochemical marker of bone formation in 
neonatal cord blood at delivery.  
 
 GG GT TT p-value GG vs. GT 
p-value 
GG vs. TT 
p-value 
GT vs. TT 
Placental 
24,25(OH)2D3, 
log(nmol/L) 
Main effect; p = 
0.04 
0.88+/- 0.27 0.62+/- 0.33 -0.24
+/- 
0.34 0.1 0.04 0.8 
Placental 
25(OH)D3, nmol/L 
Main effect; p = 0.8 
17.9+/-3.1 18.0+/-2.4 10.9+/- 3.9 >0.99 0.4 0.3 
Placental 
25(OH)D3: 
24,25(OH)2D3 
Ratio 
Main effect; p = 
0.02 
8.8+/-3.7 14.8+/-2.9 22.1+/-4.0 0.3 0.07 0.4 
Umbilical cord 
plasma OC 
ng/ml 
Main effect; p = 
0.02 
49.0+/-12.3 79.4+/-11.9 18.8+/-15.3 0.2 0.3 0.02 
Notes: Values are least-squared means +/- standard errors. Number of participants in each 
group for: placental outcomes GG (n=8), GT (n=10), TT (n=6). Number of participants in 
each group for cord blood plasma OC: GG (n=8), GT (n=8), TT (n=6). 
Abbreviations: 25(OH)D3, 25-hydroxyvitamin D3; 24,25(OH)2D3, 24,25 dihydroxyvitamin 
D3, OC, osteocalcin. 
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K. Cord OC 
GC rs7041 genotype predicted cord OC (p = 0.02). GG individuals had levels of 49.0+/-12.3 
ng/ml, GT individuals had 79.4+/-11.9 ng/ml, and TT individuals had 18.8+/-15.3 ng/ml (p = 0.02 
as compared to GT) (Figure 3, Table 3). 
 
Figure 3. Effect of GC rs7041 genotype on cord blood osteocalcin. Values are least-
squared means +/- standard errors. Number of participants in each group: GG (n=8), GT (n=8), 
TT (n=6). Groups that are not labelled with any of the same letters are significantly different 
at an α-cutoff of 0.05. 
Discussion 
This study evaluated the effects of the GC rs7041 variant on vitamin D metabolism in 
pregnant, lactating, and non-pregnant/non-lactating women consuming vitamin D intakes 
approaching the RDA. Three main findings emerged: (i) the GC rs7041 alters vitamin D 
metabolites in pregnant, lactating, and non-pregnant women, (ii) the GC rs7041 T allele is 
associated with an altered metabolic response to pregnancy, and altered placental vitamin D 
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metabolism, and (iii) neonates of women with the TT genotype exhibited lower levels of OC, 
a biochemical marker of bone formation. 
A. The GC rs7041 alters vitamin D metabolism in pregnant, lactating, and non-pregnant 
women 
Within our cohort, the GC rs7041 T allele was associated with significantly lower serum total 
25(OH)D, independent of reproductive state. Specifically, we observed lower serum 25(OH)D 
among heterozygous GT (85% of GG, p = 0.1) and homozygous TT (80% of GG, p = 0.05) 
individuals across reproductive states (Figure 1a, Table 2). This finding confirms previous 
reports of lower levels of 25(OH)D in non-pregnant women with the rs7041 T allele4,6–9, and 
expands on previous results to include pregnant and lactating women. Serum 25(OH)D is the 
primary indicator of vitamin D status and women with the rs7041 T allele may be at a greater 
risk for poor vitamin D status as compared to women with the G allele. Within our cohort, this 
genotypic effect appeared to be driven by 25(OH)D3 as we did not detect significant 
differences in 25(OH)D2 (Supplemental Figure 1, Table 2). This is not surprising in our 
cohort given that the study diet provided cholecalciferol (vitamin D3) as a dietary supplement, 
which comprised the major source of vitamin D for these women. We also observed lower 
levels of 3-epi-25(OH)D3 in GT (63% of GG, p = 0.09) and TT women (50% of GG, p = 
0.02), consistent with lower 25(OH)D (Figure 1d, Table 2).  
In addition, we observed lower DBP concentrations among individuals with the 
rs7041 T allele. Non-pregnant TT women displayed lower levels of DBP than non-pregnant 
GG women; lactating GT and TT women displayed lower levels than lactating GG women; 
and pregnant GT and TT women displayed lower DBP levels that pregnant GG women. 
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(Figure 1b, Table 2).  
Finally, homozygous TT women exhibited higher free 25(OH)D levels, 1.9x GT 
women and 2.5x GG women (Figure 1d, Table 2). Along with the evidence of lower total 
25(OH)D concentrations (comprised of free and DBP-bound forms) in TT women, this data 
supports lower levels of DBP-bound 25(OH)D among women with the variant T allele. These 
findings also appear to align with in vitro studies that report differential affinities of 25(OH)D 
for different DBP isoforms.9,19 
B. The GC rs7041 T allele is associated with an altered metabolic response to pregnancy 
Women with the GC rs7041 T allele appear to have a distinct metabolic response to 
pregnancy as compared to women with the G allele. Previously, DBP levels have been 
reported to increase by 7-152% during pregnancy.2,20–22 Within our cohort, the increase in 
DBP during pregnancy appeared to differ by rs7041 genotype. Specifically, GG pregnant 
women in our cohort exhibited 2.1x higher plasma DBP than GG non-pregnant women. 
However, this pregnancy-associated increase in DBP appeared to be dampened among 
heterozygotes, as GT pregnant women exhibited only 1.6x higher plasma DBP than GT non-
pregnant women, and differences in DBP were not detected between TT pregnant and TT 
non-pregnant women. Overall, these data suggest that the DBP metabolism is modulated by 
the rs7041 genotype during pregnancy, with no increase in TT pregnant women (Figure 1b, 
Table 2). A differential increase in DBP during pregnancy by rs7041 genotype may account 
for some of the variability between previous reports of increases in DBP during pregnancy. 
This result should be confirmed in a longitudinal study that compares DBP levels during 
pregnancy to either pre- or post-pregnancy levels in the same individual. Although it is not 
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clear why TT women fail to increase DBP levels during pregnancy, the finding indicates that 
TT women have a different metabolic response to pregnancy than GG women, and may also 
differ in the mechanism by which they source vitamin D to the placenta. 
The mechanism by which vitamin D enters the placenta is currently unknown, 
however, there are several possibilities. Placental uptake of vitamin D metabolites could occur 
preferentially via megalin-cubilin receptors, by simple diffusion in the free form, or in some 
combination of the two. DBP of maternal origin has been detected in the human placenta (22), 
providing evidence that the placenta does in fact take up DBP, though is not known whether 
this constitutes the major source of placental vitamin D. Moreover, the placental membrane 
expresses megalin-cubilin receptors (23,24) (the same receptors that the kidney uses to 
internalize DBP-bound 25(OH)D), as well as all the necessary components to make the active 
form of vitamin D (25–27), providing further rationale for placental uptake of DBP-bound 
25(OH)D. Among GG individuals, the increase in DBP during pregnancy (a known 
phenomenon), may transpire to increase the uptake of DBP-bound 25(OH)D by the tissues 
that express megalin-cubilin receptors, including the placenta. DBP-bound 25(OH)D is more 
stable and can be taken up across a concentration gradient, and thus may be favored by the 
placenta. In contrast, among TT women, the lack of increase in DBP, along with the increase 
in free 25(OH)D, suggests that in an environment with compromised DBP levels, free 
25(OH)D may be a more biologically important form of vitamin D for this genotype. Thus, 
the functional link of vitamin D with DBP, and the predominant mechanism of placental 
uptake of vitamin D during pregnancy, may differ by GC rs7041 genotype. Isotope labelling 
studies are needed to further investigate this notion.  
In addition to the lack of increase in DBP, we also observed differences in the blood 
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25(OH)D3:24,25(OH)2D3 ratio that depended upon genotype and reproductive state. While 
GG pregnant women exhibited higher 25(OH)D3:24,25(OH)2D3 ratios than GG non-pregnant 
women, we did not observe the same phenomenon in TT pregnant women as compared to TT 
non-pregnant women (Figure 1e, Table 2). Given that the 25(OH)D3:24,25(OH)2D3 ratio is 
an emerging status indicator that accounts for inter-individual metabolic differences in 
catabolizing 25(OH)D to 24,25(OH)2D, this finding is a second indication (backing up 
25(OH)D data) that pregnant women with the T allele may have lower status, or more aptly 
may not increase their vitamin D status during pregnancy like GG women. No such 
differences were detected in the metabolic response to lactation. 
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C. The GC rs7041 T allele is associated with altered placental vitamin D metabolism 
Interestingly, in line with the notion that TT individuals may source vitamin D differently to 
the placenta, they also exhibited differences in placental vitamin D metabolites. TT 
individuals exhibited non-significantly lower concentrations of placental 25(OH)D3, 
significantly lower 24,25(OH)2D3, and tended to exhibit greater placental 
25(OH)D3:24,25(OH)2D3 ratios as compared to GG individuals (Figure 2, Table 3). 
Substantially higher (nearly 3x GG) placental 25(OH)D3:24,25(OH)2D3 among TT 
individuals indicates comparatively less vitamin D catabolism relative to 25(OH)D. A 
reduction in vitamin D catabolism relative to 25(OH)D among TT individuals may transpire 
to secure the placental 25(OH)D pool as a compensatory response to the overall reduced 
presence and availability of vitamin D in TT individuals. 
D. The GC rs7041 TT genotype is associated with reduced presence of a biochemical marker 
of bone formation in neonates 
Despite high placental 25(OH)D3:24,25(OH)2D3 ratios, the neonates of TT women exhibited 
lower cord OC as compared to GT individuals (Figure 3, Table 3) suggesting that this 
genetic variant may have functional consequences for fetal bone health and bone 
development. We did not detect differences between TT and GG individuals. This could be 
due to a heterozygote effect, or alternatively could represent inadequate power. Notably, our 
entire population was highly vitamin D adequate. The effect of genotype may be more 
pronounced among women with vitamin D inadequacy. Interestingly, a recent study reported 
that lower DBP during the third trimester of pregnancy is associated with an increased risk of 
type 1 diabetes in offspring. 23 The study did not consider BMI, ethnicity, or GC genotypes 
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and found only a marginal association, but their finding is nonetheless intriguing in the 
context of our results. We observed no increase in DBP among pregnant women with the TT 
genotype and found lower osteocalcin in the cord blood of their neonates. Given that 
osteocalcin is a hormone that regulates glucose metabolism and promotes glucose tolerance, 
lower cord blood osteocalcin might contribute to the previously observed linkage between 
low DBP and type I diabetes. Furthermore, the rs7041 TT genotype has been found to modify 
the association of 25(OH)D levels with diabetes among white Americans but not black 
Americans. Specifically, among white Americans, low 25(OH)D was associated more 
strongly with diabetes in individuals with the rs7041 T allele. 24 These findings, together with 
our findings, suggest that the rs7041 T allele (most likely in the context of the Gc2 isoform of 
DBP that is the more common form among whites with the T allele) may modify the 
association between 25(OH)D levels in utero and risk of diabetes in offspring. Further studies 
are needed to clarify these relationships and determine the effect of the TT genotype and Gc 
isoforms on diabetes and bone health outcomes in infancy and early childhood. 
E. Study Limitations  
Concerns have been raised about whether the monoclonal antibody-based assay we used to 
measure DBP may have distinct immunoreactivity against the different isoforms of DBP that 
result from different genotypes. (5)  Specifically, previous studies that have used this 
monoclonal assay have found lower DBP in certain Gc types, while studies that use 
polyclonal assays or direct measurement by proteomic methods and mass spectrometry do not 
find differences by race or Gc type. (30–32) A differential affinity of the assay for the TT 
genotype as compared to the GG genotype limits the extent to which we can draw conclusions 
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from comparisons of DBP levels between genotypes. However, it would not be expected to 
interfere with comparisons within genotypes. Importantly, the finding regarding the apparent 
lack of increase in DBP during pregnancy among TT individuals is based on comparisons 
between reproductive groups within genotypes. In particular, we compared TT pregnant 
women to TT non-pregnant women.  Furthermore, given that GC polymorphisms are known 
to differ across racial and ethnic groups, we considered ethnicity in all our statistical models. 
We think this method is sufficient for our purposes and unlikely to qualitatively alter our main 
conclusions for the reasons described above; however, a direct measurement of DBP as well 
as free 25(OH)D. would have been preferable.  
In addition, these findings represent our study population and cannot necessarily be 
extrapolated to all individuals with rs7041 T allele. Combinations of this rs7041 (c.1296T>G; 
p.Asp416Glu) polymorphism and an additional SNP, rs4588 (c.1307C>A; p.Thr420Lys) 
result in three common isoforms of the vitamin D binding protein: Gc1F (rs7041 T and rs4588 
C); Gc1S (rs7041 G and rs4588 C); and Gc2 (rs7041 T and rs4588 A). The rs7041 G allele 
generally accompanies the rs4588 C allele and generates the Gc1S isoform, whereas the 
rs7041 T allele can generate either the Gc1F or Gc2 isoform, depending on the individual’s 
rs4588 genotype. The prevalence of these isoforms varies across racial groups. The Gc1F 
isoform is more prevalent among black and Asian populations; the Gc1S isoform is most 
common in whites, but among whites with the GC rs7041 T allele, the Gc2 isoform is more 
common than the Gc1F isoform. (19,32,33) Given that our study population was primarily 
white, it is likely that individuals with the T allele primarily had the Gc2 isoform rather than 
the Gc1f isoform. Because we did not have data for rs4588 (or a large enough sample size to 
include additional groups), this homogeneity in race/ethnicity helped our analysis by limiting 
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the variability; however, it also limits the extent to which these results can be extrapolated to 
other Gc types. It is worth mentioning that all TT pregnant women all carried female infants. 
This was considered in all our statistical models, and infant sex did not have a significant 
bivariate relationship with any of the placental outcomes or cord OC.  
Although the rs7041 T allele appears to be a risk allele in our study and previous 
studies that have identified lower 25(OH)D or increased risk of diabetes (29), one study by 
Chun et al. identified a protective effect of the rs7041 T allele during pregnancy. They 
reported that GC rs7041 modifies the effect of low 25(OH)D on infant birth weight. 
Specifically, low maternal serum 25(OH)D predicted risk of low birth weight among pregnant 
women carrying the GC rs7041 G allele, but not among pregnant women homozygous for the 
T allele. (34) What is beneficial for one health outcome can be disadvantageous for another, 
and it is possible that the rs7041 T allele is a risk allele in some disease contexts, and 
protective in others. It is also pertinent to consider that the rs7041 T allele in the Chun et al. 
study may be more representative of the Gc1f isoform than the Gc2 isoform. Chun et al. did 
not report information on Gc types of their participants or their ethnicities, but their study was 
conducted in a South Korean population, and the Gc1f isoform is more common in Asian 
populations. Notably, the Gc isoforms have been found to have differential affinity for 
vitamin D metabolites, with Gc1F displaying the highest affinity and Gc2 the lowest. (19) 
Therefore, it is also possible that the rs7041 T allele represents a risk allele in the context of 
the Gc2 isoform, but is protective in the context of the Gc1f isoform. Studies that examine 
these outcomes in greater depth and in relation to the Gc types themselves will surely provide 
further clarity. 
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Conclusion  
Our study demonstrates that the GC rs7041 genotype alters vitamin D metabolism, as well as 
the metabolic response to pregnancy, and a marker of bone formation in neonates. Notably, 
although DBP is known to increase markedly during pregnancy, this phenomenon was 
observed only in individuals with rs7041 GG or GC genotypes; pregnant TT women in our 
cohort did not exhibit higher DBP than non-pregnant women. The genotypic differences in 
DBP status during pregnancy may have implications for placental vitamin D transport and 
availability of vitamin D to the mother and fetus. Future studies with larger sample size are 
needed to comprehensively characterize the effects of the three common Gc isoforms on 
vitamin D metabolism during pregnancy and the consequences of these metabolic differences 
for maternal, fetal, and infant health. 
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Supplemental Information 
 
(a) 
 
(b) 
	
Supplemental Figure 1. Effect of the GC rs7041 genotype on serum 25(OH)D2 & serum 
25(OH)D3. Values are least-squared means +/- standard errors. Number of participants in each 
group: GG (n=18), GT (n=36), TT (n=20). Groups that are not labelled with any of the same 
letters are significantly different at an α-cutoff of 0.05 
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